Accepted Manuscript



Dengue drug discovery: Progress, challenges and outlook

Siew Pheng Lim

PII: S0166-3542(18)30562-X

DOI: https://doi.org/10.1016/j.antiviral.2018.12.016

Reference: AVR 4440

To appear in: *Antiviral Research*

Received Date: 17 September 2018

Revised Date: 22 December 2018

Accepted Date: 25 December 2018

Please cite this article as: Lim, S.P., Dengue drug discovery: Progress, challenges and outlook, *Antiviral Research* (2019), doi: https://doi.org/10.1016/j.antiviral.2018.12.016.

Dengue drug discovery: progress, challenges and outlook

Siew Pheng Lim

Denka Life Innovation Research, 21 Biopolis Road, 03-21/22, Nucleos, Singapore 138567.

Tel: +65 62652154; Email: siewpheng-lim@denka.com.sg

Keywords: Drug discovery; antiviral; dengue virus; flavivirus

Abbreviations: ADME, absorption, distribution, metabolism, and excretion; C, capsid; CC_{50}, half maximal cytotoxic concentration; DAA, direct antiviral agent; DENV, dengue virus; DHF/DSS, dengue hemorrhagic fever/dengue shock syndrome; DSF, differential scanning fluorimetry; EC_{50}, half maximal effective concentration; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HTS, high-throughput screening; IC_{50}, half maximal inhibitory concentration; ITC, isothermal calorimetry; JEV, Japanese encephalitis virus; M, membrane; MTS, medium throughput screening; MTase, methytransferase; NI, nucleoside analog inhibitors; NNI, non-nucleoside inhibitor; NS, non-structural; PAHO, Pan American Health Organization; PK, pharmacokinetics; RdRp, RNA-dependent RNA polymerase; SAR, structure-activity relationship; S/B, signal-to-background noise; SPA, scintillation proximity assay; TDR, Special Programme for Research and Training in Tropical Diseases; TI, therapeutic index; WHO, World Health Organization; WNV, West Nile virus; YFV, yellow fever virus; ZIKV, Zika virus.

Abstract

In the context of the only available vaccine (DENGVAXIA) that was marketed in several countries, but poses higher risks to unexposed individuals, the development of antivirals for dengue virus (DENV), whilst challenging, would bring significant benefits to public health. Here recent progress in the field of DENV drug discovery made in academic laboratories and industry is reviewed. Characteristics of an ideal DENV antiviral molecule, given the specific immunopathology provoked by this acute viral infection, are first described. New chemical classes identified from biochemical, biophysical and phenotypic screens that target viral (especially NS4B) and host proteins, offer promising opportunities for further development. In particular, new methodologies ("omics") can accelerate the discovery of much awaited flavivirus specific inhibitors. Challenges and opportunities in lead identification activities as well as the path to clinical development of dengue drugs are discussed. To galvanize DENV drug discovery, collaborative public-public partnerships and open-access resources will greatly benefit both the DENV research community and DENV patients.

Contents

1. Dengue: a growing global health problem and unmet medical need

DENV belongs to the family of Flaviviruses, which includes other disease-causing viruses such as Zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and yellow fever virus (YFV). The virus has a single stranded, plus-sense viral RNA genome of approximately 11,000 nucleotides in length that encodes three structural (C, Env, M) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5; Lindenbach et al., 2007; Chambers et al., 1990). DENV infects host cells such as monocytes by first attaching to cell surface receptors, followed by cell entry via a clathrin-dependent entry pathway (Fig. 1). After fusion of the virus envelope with endosomal membrane, the viral RNA is released into the cytosol and translated on the rough endoplasmic reticulum (ER) membrane. Translated DENV non-structural (NS) proteins re-organize the ER membrane to form replicative complexes within double-membrane vesicles, where viral RNA replication and virus assembly is initiated (Chatel-Chaix and Bartenschlager, 2014).

Dengue virus-associated diseases are major causes of illness and death in the tropics and subtropics, with as many as 400 million people infected yearly (Bhatt et al., 2013; Brady et al., 2012; Shepard et al., 2016). Four serotypes of dengue viruses (DENV1-4), co-circulate in more than 140 countries (Shepard et al., 2016). It is the tenth highest cause of both mortality and morbidity in developing countries and the leading cause of death in children below 15 years old in some South-East Asian countries (Global Health Data Exchange Results Tool, IHME, 2017). Dengue is a worldwide problem due to increased territorial expansion of both dengue viruses and its vector, the *Aedes* (*Ae.*) mosquitoes. With the current trends in human behaviour (population growth, people movement, urbanization, ineffective vector control) and climate changes (due to global warming), continual geographical spread of dengue diseases is anticipated (Halstead, 2008; WHO Fact sheet on dengue).

Co-circulation and frequent large outbreaks of dengue, chikungunya (CHIKV) as well as other flaviviruses such as ZIKV, WNV, YFV in South-east Asia and/or the Americas, pose further public health challenges (Paixao et al., 2018; WHO, 2016-2018, Disease Outbreak news). Patients with these diseases present very similar initial clinical symptoms (flu-like symptoms, high fever, headache, nausea, rash, body pain) with slow and long convalescence phases. Dengue diseases result in approximately 500,000 annual hospitalisations, with increased risks of dengue hemorrhagic/shock syndrome (DHF/DSS) during secondary infections (WHO Fact sheet on dengue). The Pan American Health Organization (PAHO) and WHO recently published guidelines for clinical diagnosis to differentiate between these febrile viral diseases and for the clinical management of infected patients (Tool for the Diagnosis and Care of Patients with Suspected Arboviral Diseases. March-2017, PAHO). In the absence of effective prophylactic and therapeutic measures against DENV, patient management is focused on supportive therapy and the control of onward transmission (WHO Global Strategy for dengue prevention and control, 2012-2020). The economic burden of dengue diseases is estimated at 1.9 million DALYs in developing countries (Global Health Data Exchange Results Tool, IHME, 2017).

Extensive research efforts from a large number of public and private institutions have provided insights into the epidemiology, evolution (Sims and Hibbard, 2016; Holmes and Twiddy, 2003) and molecular biology (Lescar et al., 2018; Barrows et al., 2018; Apte-Sengupta et al., 2014) of dengue virus. Similarly, investigations into virus-host interactions (Perera et al., 2017; Acosta et al., 2014) and the immune response to dengue has enabled better understanding of virus pathology (Mathews, 2018; Rivio, 2018; Diamond et al., 2015; Simmons et al., 2015). These knowledge have cumulated in significant undertakings in dengue vaccine development (Silva et al., 2018) and drug discovery (reviewed in Hernandez-Morales et al., 2018; Whitehorn et al., 2014; Lim et al, 2013a; Noble et al, 2010). Nevertheless, there are still much that we do

not know and need to work towards, if we are to deliver safe and effective dengue vaccines (Halstead 2018; Silva et al., 2018) and therapeutics (Lim et al., 2013a).

Previously, we reviewed the progress in dengue drug discovery made at the Novartis Institute of Tropical Diseases (NITD) as well as the major discoveries made by academia and other companies (Lim et al., 2013a). This review examines the advancements made in this field since 2013, the opportunities and continued challenges that exist and provides perspectives on future directions. Preferred pharmacokinetics and pharmacodynamics profiles of a DENV drug and recommendations for compound progression in the different phases of DENV drug discovery, from hit identification to preclinical testing, as well as challenges in the path to clinical dvelopment of dengue drugs, are also discussed. Where applicable, excellent reviews on specific topics will be highlighted and readers are strongly encouraged to refer to these for in-depth study.

2. Feasibility and target product profile of dengue antiviral therapy

Key challenges to the success of dengue therapeutics are the rapid decline in patient viremia (<1 week duration) during the febrile phase (Libraty et al., 2002a, b; Nguyen et al., 2013) and reluctance (difficulty?) in patients seeking early medical attention. The latter may become less of an issue when an effective antiviral becomes available and necessary infrastructure for drug distribution are put in place. To identify and treat patients early, low-cost, rapid and sensitive diagnostics are critical, especially to discriminate between dengue, and other endemic febrile-causing infectious agents such as malaria, CHIKV and ZIKV. Current commercial immuno-detection assays (rapid lateral flow assays and ELISA for NS1 and anti-dengue envelope antibody detection) and nucleic acid detection technologies (NAT) such as reverse transcription (RT)-qPCR do not meet these requirements for field diagnosis, arguing for

the development of more innovative rapid and sensitive diagnostics and identification of predictive biomarkers, especially for assessing progression into DHF/DSS (Nhi et al., 2016; John et al., 2015; reviewed in Low et al., 2018).

Whilst serological IgG/IgM immuno- detection assays are fast and relatively affordable, they have lower sensitivities and are cross-reactive amongst Flaviviruses, making them unsuitable for evaluating individuals with prior flaviviral infections and/or vaccination. Additionally, anti-DENV antibodies are more reliably detected during the later stage of fever/symptom onset as the adaptive immune system takes time to generate humoral response. Although NS1 antigen immuno-detection assays can be used at early infection stages, they suffer from lower sensitivity and variability, depending on the serotype and patient immune status (Chung et al., 2015). Current DENV NAT assays are mainly laboratory-based and are expensive and not rapid (reviewed in Goncalves et al., 2018). That severe dengue diseases is linked to higher viremia levels, supports the hypothesis that reducing viremia early will lower the risks of developing DHF/DSS (Saroch et al., 2017; Lim et al., 2013a). This is also supported by studies that show reduction of virus levels and suppressed inflammatory responses after treatment of DENV infected mice with small molecules against viral (Schul et al., 2007) or host factors (Morrison et al., 2017; Pinto et al., 2015). Nevertheless, the validation of this proposition in a clinical setting will be challenging as <1 % of dengue patients develop into DHF/DSS (as discussed in Lim et al., 2013a).

Requisite key characteristics of a dengue drug (target product profile) have been described previously (Hernandez-Morales et al., 2018; Whitehorn et al., 2014; Lim et al., 2013a; Keller et al., 2006). An ideal DENV drug should be fast-acting (due to rapid viremia decline), equally active against the four DENV serotypes, lessen disease symptoms, shorten days of illness and reduce the risks of disease severity. In terms of drug development, fewer synthesis steps would

be advantageous (to reduce the cost of goods for developing countries), as well as oral administration and a long shelf-life, with stability at high temperature and relative humidity (up to 40 ^{o}C and 75 %, respectively) to facilitate distribution and storage (WHO Technical 62 Report Series). The drug may act via inhibition of either a DENV or host target, but must possess a good safety window (ideally suitable for dosing in young children, pregnant women and elderly) with a low propensity for drug-drug interaction (suitable for combination therapy and for individuals with other health complications). Since DENV is an acute infection, it is envisaged that dosing will not exceed one week. However, this may change, if the drug is shown clinically to be capable of reducing severe DENV diseases or have prophylactic utility.

Emergence of viral resistance to direct acting anti-DENV drugs (DAAs) should be low, when short-term treatment is given. Nevertheless, poor patient compliance or management may still contribute to drug resistance or selection of pre-existing variant strains with drug resistant or compensatory mutant epitopes (Alexander et al., 2012; Guedi et al., 2010). On this note, the use of new technologies such as next-generation sequencing to study the genetic diversity of virus populations or virus dynamics under selective drug pressure, should shed some light on this area, as is being evaluated for HIV, HCV, Ebola and influenza (Brumme and Poon, 2017; Leung et al., 2017). Likewise, careful consideration of a DENV drug for prophylactic use (i.e. pre-exposure prophylaxis) is important, as a sub-optimal dosing regime may also lead to resistant virus development.

Due to the lack of proof-reading function in dengue virus NS5 polymerase, its nucleotide incorporation error rate is estimated to be around 10^{-5} mutations per nucleotide per replication cycle (Jin et al., 2011; Castro et al., 2005). The resultant virus quasispecies present within the host and also at the population level, can induce the emergence of drug-resistant virus strains following DAA therapy. The actual frequency of inhibitor-resistant mutants is dependent on (i)

the number of amino acid substitutions required for resistance, (ii) the genetic barrier (number and type of mutations needed for the amino acid substitutions), and (iii) the fitness cost that the mutations entail. Resistance to inhibitors often requires one or a few mutations, and there are potentially multiple, alternative mutations that can confer resistance to a drug, residing directly in the viral drug target or its interacting viral protein partner(s) (Domingo et al., 2012). To safeguard against escape virus mutants, combination drug therapy that either target different viral proteins (e.g. NS2/3 protease and NS5 polymerase) or host (e.g. alpha-glucosidase) and viral proteins are necessary. This strategy has been shown to be effective, as exemplified by the current treatment of HCV infections. The most recently approved HCV DAA regimens are pan-genotype (GT), once-daily, all-oral DAA combinations of Glecaprevir/pibrentasvir (anti-NS5A/NS4A/3 protease) and sofosbuvir/velpatasvir/voxilaprevir (anti-NS5B (NI)/NS5A/NS4A/3 protease) (reviewed in Couchet et al., 2018; Vermehren et al., 2018).

Finally, whilst the ideal DENV DAA should be equally effective across all four DENV serotypes, this may be somewhat challenging due to serotype amino acid sequence dissimilarity in the viral structural and non-structural proteins (e.g. NS4B sequence is 78–85% identical in DENV1-4; Lindenbach et al., 2007). This scenario has been observed for HCV DAAs. In the case of the anti-NS5A drug, Daclatasvir (formerly BMS-790052), EC_{50} values in HCV replicon assays for GT-1a and -1b, were 50 pM and 9 pM, respectively, but ranged from pM to low nM for replicons with NS5A derived from GT-2a, -3a, -4a, and -5a (Gao et al., 2010). Similarly, EC_{50} values of HCV polymerase NI, SOVALDI® (Sofosbuvir; formerly PSI-7977) in HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a or 6a replicon assays, ranged from 0.014 to 0.11 μM (Hebner et al., 2012; SOVALDI® prescription data sheet, Gilead Sciences, Inc). Such divergence in genotypic or serotypic inhibition in DAA treatment argues for virus typing during clinical diagnosis and the application of combination therapy to ensure better treatment outcomes.

3. Pharmacokinetics and pharmacodynamics profiles of a dengue drug

In terms of its pharmacokinetics (PK) profile, a good DENV drug candidate should possess sufficient solubility and stability in the gastro-intestinal tract and liver, and be well-absorbed (good permeability), to permit systematically distribution (since DENV has been shown to have wide cell tropism). The physicochemical properties of the drug greatly influence these factors and a good oral drug is based on a balance of these features (Lipinski rule of 5; Lipinski et al., 1997). Limited drug absorption via the gut, early biotransformation and elimination in the liver and kidney can significantly reduce the amount of orally administered drug that enters the systemic circulation. Other preferred PK parameters include good bioavailability and volume of distribution, medium to long half-life, medium to low clearance, to (ideally) enable once a day oral dosing (to facilitate easy patient compliance). Once absorbed systemically, the drug in the blood may be protein or lipid bound or exist in a free soluble form. Only the free soluble form of the drug is taken up by target organs and cells, as well by the kidney for elimination. Similarly, within a cell, it is the unbound fraction of a drug that exerts therapeutic effect on its target.

An ideal DENV drug should possess a wide therapeutic window (or good safety margin) between the efficacious the dose range and the toxic dose. Drug efficacy is initially determined from *in vitro* assays (e.g. EC_{99}, EC_{90}, EC_{50} and IC_{50} values) and next, in animal models and human patients. However, *in vitro* biochemical and cell-based assays are typically 'closed" or isolated systems where the provided drug and target concentrations are in equilibrium during the course of the experiment. *In vivo* systems, on the other hand, are "open" systems, where drug and target concentrations fluctuate with time. Both *in vitro* and *in vivo* efficacy outcomes are strongly influenced by drug-target interactions such as the binding affinity and specificity of the drug to its target (K_a, K_d). For *in vivo* efficacy, drugs with longer residence time (t_R) have been shown to have better biological efficacy (Lu and Tonge, 2010). Improving drug-target residence

time (measured as $1/k_{off}$, the reciprocal of the dissociation rate constant, k_{off}) is a key driver during drug discovery to achieve *in vivo* success (reviewed in Copeland, 2016). Other important factors that influence drug efficacy include the highest (C_{max}), and lowest (C_{min}, C_{trough}) drug plasma concentrations achieved after dosing as well as the time (T_{max}) to attain these parameters. To retain pharmacological effects, the free drug plasma concentration should be well-above the EC_{50} value, and ideally above the EC_{90} or EC_{99} values during the entire course of each dosage (trough free drug concentration). This reduces the likelihood that remaining virus attains drug resistance mutations during subsequent rounds of replication (Drusano et al., 2001).

In the absence of an orally bioavailable drug, intravenous drug administration in hospitals or settings that allow patient monitoring should not be ruled out. PK profiles of drug candidates are typically assessed during pre-clinical studies on animal species and in phase I clinical trials on healthy human volunteers. In some developing countries, DENV patient populations may be under-nourished or have other health issues. This may result in changes in drug absorption, distribution, or elimination. Thus, DENV drug dosing regimes in phase II/III clinical trials to determine efficacy ought to consider these possible variance. DENV is not reported to cause in utero infection nor is considered a non-neurotropic virus (Li et al., 2017). Dengue drugs, thus need not be specifically designed to pass the blood-brain barrier nor cross the placenta, which may present additional development hurdles.

4. Approaches to find dengue virus inhibitors

Hit finding approaches to obtain new chemical starting points for DENV targets include the use of biochemical, biophysical and cell-based assays to screen compound libraries, either with diverse chemical scaffolds or target-focused compounds (focused library). Aided by available X-ray crystal structures of a number of DENV proteins, researchers utilized

computational sreening approaches, such as *in silico* compound docking (virtual screening) and rational, structure-based drug design (SBBD) to identify potential inhibitors. These latter methodologies have yielded successful drug candidates, in other infectious diseases, such as HCV and HIV. SBBD may also be applied to the design of new drugs to overcome viral resistance, through mapping resistant epitopes to the X-ray structure of the target proteins, like HIV-1 and HCV protease (Yilmaz et al., 2016) and influenza neuraminidase (Prachanronarong et al., 2016).

The following sections highlight recent discoveries made by researchers (since 2013) using these different methodologies in the quest to identify novel DENV inhibitors (Sections 4.1-4.9) and the extent the hits are validated (Tables 1-6). Criteria and methodologies for compound progression from hit-to-lead, lead optimization, and candidate drug selection that are relevant to DENV drug discovery, are described in the Supplementary Materials.

4.1. Biochemical assays

Over the years, DENV enzymes, NS2B/3 protease (Erbel et al., 2006; Li et al., 2005; Leung et al., 2001; Yusof et al., 2000), NS3 helicase/NTPase/RTPase (Basavannacharya and Vasudevan, 2014; Wang et al., 2009; Benarroch et al., 2004), NS5 methyl-transferase (Barral et al., 2013; Lim et al., 2013b, 2011, 2008; Chung et al., 2010) and NS5 polymerase (Niyomrattanakit et al., 2015, 2010; Selisko et al., 2006; Nomaguchi et al., 2003) were systematically studied. Biochemical assays for these proteins, based on fluorescence or radioactive nucleotide incorporation were developed and used for inhibitor identification. DENV enzyme functional and structural characterization, inhibitor identification and profiling in biochemical, binding or cell based assays, have been discussed in-depth for NS2B/3 protease (Leonel et al., 2018; Nitsche, 2018; Luo et al., 2015; Lim et al., 2013a, Noble et al., 2010), NS3

helicase/NTPase/RTPase (Luo et al., 2015; Lim et al., 2013a), NS5 methyl-transferase (MTase) and NS5 polymerase (Lim et al., 2015, 2013a; Bollati et al., 2010).

Different in-house libraries and commercial compound libraries have been interrogated for new chemical starting points with DENV biochemical assays. The compound library sizes ranged from a few hundred to a million compounds (Table 1). More recent screening campaigns have yielded potent inhibitors for NS2B/3 protease (Beesetti et al., 2018; Weng et al., 2017; Balasubramanian et al., 2016; Wu et al., 2015) and NS3 helicase (Sweeney et al., 2015) with activity in DENV cell-based assays. More detailed descriptions of NS2B/3 protease inhibitors have been reviewed by Leonel et al. (2018) and Nitsche (2018). Finding good starting points for NS5 MTase and polymerase from compound screening with in vitro enzyme have thus far been less fruitful. This may be due to the absence of suitable starting points in the compound libraries and also the highly intractable nature of these protein targets. For example, majority of marketed drugs that against viral DNA (from HSV, HCMV, VZV) and RNA polymerases (from HIV, HBV, HCV, RSV) are nucleoside inhibitors (De Clercq and Li, 2016). Many of the hits identified from the Novartis compound library bound in or near the RNA tunnel in the apo-NS5 polymerase (Smith et al., 2014b; Noble et al., 2013; Niyomrattanakit, 2011; Yin et al., 2009). Subsequent medicinal chemistry follow-ups to generate SAR and improve potency were often challenging due to weak binding affinities, as well as high MWs and lipophilicity of the hits. Using the NS5 *de novo* initiation assay, Pelliccia et al. (2017) and Benmansour et al. (2016) identified new promising scaffolds, with low micromolar activities in the enzyme and cell-based assays. One frequent trend that occurs from biochemical studies is the lack of hit validation with biophysical assays and confirmation of on-target inhibition in cell-based assays (refer to Table 1). With further compound characterisation and medicinal investigation, recently identified hits

297 can hopefully be ascertained to interact specifically with their respective viral enzyme targets
298 and translate into amenable leads.
299
300 **4.2. Biophysical assays**
301 A number of biophysical assays such as fluorescence quenching, SPR (surface plasmon
302 resonance), ITC (isothermal calorimetry), DSF (differential scanning fluorimetry or thermal
303 shift), X-ray crystallography, NMR (nuclear magnetic resonance) have been established for
304 DENV NS3 (reviewed in Luo et al., 2015; Noble et al., 2010; Bodenreider et al., 2009) and NS5
305 (reviewed in Lim et al., 2015). These binding assays are useful tools to validate hits from high
306 throughput screening and for hit-to-lead activities. They have also been used successfully for
307 compound screening (Table 2). Both in-house libraries and commercial compound libraries have
308 been employed for identification of new chemical starting points, with library sizes ranging from
309 a few hundred to several hundred thousand compounds (Table 2). Binding assays to identify
310 inhibitors that prevent protein-protein interaction have also been developed for DENV proteins.
311 Using alphascreen technology, inhibitors have been found for envelope protein (Lian et al.,
312 2018) and NS5 (Tay et al., 2013) which have good potency in DENV cell-based assays. A report
313 by Yao et al. (2018) described the identification of a quinazolinone derivative, Q63, that inhibits
314 NS5 RdRp, following compound screening by SPR. Q63 shows good DENV-1, -2, -4 inhibition
315 in cells with EC_{50} values ranging from 1.7–2.1 μM. In addition, researchers have used
316 competitive ligand binding assays to screen for inhibitors. Stahla-Beek et al. (2012) used a
317 fluorescent-labeled GTP (GTP-bodipy) to screen for inhibitors to NS5 MTase and identified BG-
318 323. By generating a A125C NS2B/3 protease mutant, Yildiz et al. (2013) used cysteine reactive
319 probes to develop a screen which can be used to identify protease inhibitors.

Fragment-based drug discovery (FBDD) by X-ray crystallography has recently been successfully used to develop potent cellular active inhibitors against NS5 polymerase (reviewed in Lim et al., 2018). Starting from a hit, JF-31-MG46, that binds weakly to a novel pocket in DENV3 RdRp and is inactive in DENV cell-based assays (DENV1-4 RdRp K_d and *dn*I IC_{50} value = 610 and 734 μM, respectively; DENV1-4 EC_{50} >50 μM), the most active derivatives (compound **27**, **29**, **29i**) inhibited DENV1-4 infection at low-to-high micromolar concentrations (Table 2). Fragment based screening by DSF with NS5 MTase and NS3 helicase have also been performed. Whilst no hits were obtained for helicase, seven hits were found for NS5 MTase (Coutard et al., 2014). By linking two fragments, the group was able to further improve inhibitor potency Benmansour et al., 2017). One advantage of using fragments as a starting points is that they often have higher ligand efficiencies and binding is driven by hydrogen bond interactions. This increases the likelihood that the final optimized ligand will not be too hydrophobic (log P < 5). To date, eighteen drug candidates discovered by FBDD have advanced to clinical trials so far (Erlanson et al., 2016; Velvadapu et al., 2015). There are two FDA-approved drugs derived from fragment-based approaches, Zelboraf® (vemurafenib, PLX4032; targets B-Raf-V600E mutant enzyme, for treatment of late-stage melanoma; Bollag et al., 2012) and Venclexta (Venetoclax; targets B-cell lymphoma-2 (BCL-2) for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); Scheffold et al., 2018). Nevertheless, due to the need for strong computational and medicinal support in FBDD, some groups may be hesitant to embark on this approach.

4.3. Structure based drug discovery

In general, structure based drug discovery (SBDD) for DENV has mainly been used to pursue peptidiomimetics against NS2B/3 protease (Table 3). These have resulted in peptidic

inhibitors with submicromolar activities in in vitro protease assays and high micromolar activities in DENV cell-based assays (Lin et al., 2017, 2016; Nitsche et al., 2017, Takagi et al., 2017). Whilst the focus is on targeting the P1-P4 sites in the NS2B/3 protease (Nitsche et al., 2017, Takagi et al., 2017; Behnam et al., 2015), Lin et al. (2017, 2016) reported success in targeting the P' sites with cyclic peptides, to inhibit this enzyme. To date, the most potent peptide inhibitor, **103**, was described by Behnam et al. (2015), with DENV2 K_i = 18 nM; EC_{50} = 3.4 μM. The compound library size described by researchers using the SBDD approach, are typically smaller (<100) as each peptidic inhibitor is custom synthesized. Rational design approaches have also been attempted for DENV capsid (Faustino et al., 2015a, b, 2014), NS5 RdRp (Xu et al., 2016) and MTase (Lim et al., 2011). DMB220, an RdRp inhibitor, showed encouraging pan-DENV1-4 inhibition in both biochemical and cell-based assays (Xu et al., 2016; Table 3). Comprehensive reviews of the DENV envelope peptide inhibitors that block virus entry (Chew et al., 2017) and NS2B/3 (Nitsche, 2018; Chew et al., 2017; Lim et al., 2013a) peptide inhibitors have previously been undertaken and readers are encouraged to refer to them for more details.

4.4. Virtual screening

Many groups have conducted in silico compound docking to screen for molecules that bind to DENV envelope, NS2B/3 protease, NS3 helicase, NS5 MTase and NS5 RdRp. However, these virtual hits were not always validated further by biochemical or biophysical assays. Table 4 lists the recent in silico docking hits that were further assessed by DENV biochemical and cell-based assays for inhibitory activities, although the confirmation of on-target effect in cells was not reported. If compound resistant DENV replicons or viruses could be raised, it will certainly help to support the lead optimisation phase. Majority of the compounds used for virtual

screening originated from commercial or public sources, with library sizes ranging from thousands to millions of compounds. Brecher et al. (2017) reported a highly potent allosteric NS2B/3 protease inhibitor, NSC135618, that has good activity in the biochemical and cell-based assays (DENV2 IC_{50} = 1.8 μM; EC_{50} = 0.81 μM). Similarly, active NS2B/3 protease inhibitors were also identified by docking into the open form of DENV2 NS2B/3 protease (Pelliccia et al., 2017; Cabaracas-Montalvo et al., 2016; Li et al., 2015; Table 4). By docking compounds into the DENV envelope octyl β-glucoside binding pocket, Leal et al. (2017) identified compounds with low micromolar inhibitory activities in DENV cell-based assay. Vincetti et al., 2015 performed virtual docking into the allosteric site (cavity B) of DENV3 NS5 RdRp and identified a compound, **16i**, that may inhibit NS3-NS5 interaction (Table 4). Using an in-house library of HCV NS5B inhibitors, Taratino et al. (2016) discovered different classes of DENV RdRp inhibitors that showed low to submicro-molar IC_{50} values in the RdRp dnI assay. Whilst compound **8** was inactive in DENV cell-based assays, HeE1-2Tyr was inhibited DENV1-4 replication. X-ray crystallography data shows that HeE1-2Tyr binds in the same region as NITD-107 (Noble et al., 2013) and forms self-interactions.

4.5. Cell-based assays

Phenotypic screens with diverse compound libraries against three different types of DENV cell-based assays (subgenomic luciferase reporter replicon, whole virus infection followed by IFA or cytopathic readouts) have together, yielded a variety of inhibitor classes that act on both viral and host targets (Table 5). Library sizes ranged from a few hundred to more than a million compounds from both commercial and proprietary sources. Earlier hit finding outcomes (till 2013) were extensively discussed in Lim et al., 2013a and will not be revisited here. Some newly identified host targets that impact DENV replication in cells, include protein tyrosine kinase

(Abl, fyn, AXL; de Wispelaere et al., 2018), mitogen-activated protein kinase (Smith et al., 2014a) and TRIF-dependent signalling cascade (Pryke et al., 2017; Table 5).

More recent explorations discovered inhibitors to viral targets such as capsid (Smith et al., 2018, Scaturro et al., 2014), envelope (Chu and Yang, 2007), NS4A (Nobori et al., 2018), as well as protease (Lu et al., 2018; Yang et al., 2014). No inhibitors to DENV NS5MTase or polymerase have been identified from phenotypic screens. On the other hand, new chemical entities that act on DENV NS4B continue to be found (Bardiot et al., 2018; Hernandez-Morales et al., 2017, Wang et al., 2015; Zou et al., 2015; Table 5), making it the most frequent hit in screening campaigns (reviewed in Xie at al., 2015). Notably, NS4B residue T108I and the double P104L/A119T mutation conferred resistance to inhibitor, JNJ-1A (DENV1-4 EC_{50} = 0.7 μM, Hernandez-Morales et al., 2017), indicating that like 2DM25N (van Cleef et al., 2013), it targets the same region as NITD-618 (Xie et al., 2011).

Nevertheless, further development of JNJ-1A is challenging as it exhibits suboptimal physicochemical properties, inhibits cytochrome enzyme activities and has *in vitro* mitchondrial toxicity (Hernandez-Morales et al., 2017). Unfavourable physicochemical properties (low solubility, high lipophilicity, instability and short half-lives) were also observed in other NS4B compounds (**12a**, **14a,** NITD-618) including compound **29**, derived by by scaffold morphing (Kounde et al., 2017). This is not surprising, given that NS4B is a membrane protein, and forms extensive interactions with itself and other viral proteins such as NS4A and NS2B-NS3 (Xie et al., 2015). Nevertheless, through chemical derivatization of compound **12a**, Bardiot et al. (2018) have obtained a more stable analog, **100a,** with better stability and solubility and oral bioavailability of 64%. This report indicates that given time and perseverance, physicochemical and PK challenges in NS4B inhibitors can be overcome, as has been seen for the development of HCV NS5A inhibitors (Kohler etal., 2014).

4.6. NS5 nucleoside analogs

Nucleos(t)ide analogs or inhibitors (NIs) are effective anti-virals, as evinced in the standard treatment of HSV, HCV, HBV and HIV-1. Whilst NIs offer the advantage of broad spectrum activity against different virus genotypes and strains, development of this class of inhibitors presents many challenges. NIs must be delivered to the right host compartments, and be adequately converted by host enzymes (cellular kinases) in the target cell types, to their active triphosphate forms, to exert inhibitory effects. In vivo toxicity of NIs, is often a big hurdle, and is not readily predictable. Tissue- and cell-specific toxicity has been strongly correlated with the inhibition of host cell enzymes such as host polymerases, particularly the mitochondrial enzymes, DNA polymerase (Pol) γ (Johnson et al., 2001) and RNA Pol (Fenauz et al., 2016; Feng et al., 2016; Arnold et al., 2012a). Moreoever, Pol beta (Brown et al., 2011) and PrimPol (Mislak and Anderson, 2015) have been shown to localise to the mitochondria and to incorporate nucleoside analog reverse-transcriptase inhibitors (NRTIs). Toxicity caused by NIs may also be due to induction of mitochondrial electron transport chain dysfunction, increase in oxidative stress (NRTIs, Smith et al., 2017; Lund and Wallace, 2004), and reduction in levels of natural NTPs. These effects can be due to interaction with nucleos(t)ide-binding enzymes such as thymidine kinase (AZT, Lynx et al., 2006), inosine MP dehydrogenase (ribavirin; Graci et al., 2006) and nucleoside transporters (HSV and HIV-1 NIs; Koczor et al., 2012). Nevertheless, in vitro assays for DNA and RNA Pols, cytotoxicity assays have been developed to mitigate NI toxicity (Jin et al., 2017; Young, 2017; Chen et al., 2015; reviewed in Feng, 2018). Structural data of NIs bound to polymerase γ (Szymanski et al., 2015) or RNA Pol (Arnold et al., 2012b), can provide additional guidance.

NIs that have anti-DENV effects are summarised in Table 6. Early NIs were previously described in Chen et al. (2015) and in vivo toxicity manifested by many of these NIs, may be

partly attributed to inhibition of mitochondrial RNA Pol. A recent paper by Wang et al. (2018) described the anti-DENV activities of a series of 2'-substituted uridine phosphoramidate prodrugs (Table 6) and their in vitro toxicity profile. Both 2'-fluoro-2'-C-methyl uridine-triphosphate (the HCV NI, sofosbuvir-triphosphate) and the most active anti-DENV compound, 2'-C-ethynyl-4'-F-uridine (**37;** IC_{50} = 0.65 μM), are poor substrates for mitochondria RNA Pol, did not affect mitochondria protein synthesis and did not show cytotoxicity in three different cell lines tested (CC_{50} >50 μM in HepG2, K562, MT-4). However, sofosbuvir-triphosphate is a poor inhibitor of DENV RdRp (IC_{50} = 15-18 μM; Table 6). As previously noted in Potisopon et al. (2017), the presence dengue DENV (and ZIKV) RdRp, unlike HCV, are inhibited by NI substitutions in the order : 2'-C-Me> 2'-C-Me-2'-F, unlike HCV RdRp. Lin et al. (2018) studied the effects of nucleobases as alternative starting points for DENV inhibition. Instead of utilising host kinases to generate monophosphates of the NIs, nucleobases are converted by 5-phosphoribosyl-1-pyrophosphate to give the corresponding nucleoside-5'-monophosphate. Unfortunately, most of the nucleobases tested were either weakly active or rather cytotoxic in Huh7 cells. Trityl□containing uridine analogs were also tested for anti-DENV activity, with several compounds showing low micromolar inhibitory activities. biological activity (Table 6). Whilst trityl moieties are generally added as protective groups during chemical synthesis, there have been a few reports indicating that they possess biological activity (Palasz and Ciez, 2014).

4.7. Viral RNA binding proteins

A number of host pathogen recognition recptors (PRRs) such as RIG-I, MDA-5, TLR-3 have been reported to restrict DENV replication (Liang et al., 2011; Nasirudeen et al., 2011). DENV RNA synthesis occurs in the viral replicative complex within ER-associated double-membrane vesicles in the cytoplasm (reviewed in Lescar et al., 2018). A number of host proteins

have been shown to regulate viral RNA cap formation (e.g. EIF4E), replication (stress granule proteins, P-body proteins), as well as translation (e.g. PABP, EIF4F, ribosomes), viral RNA encapsidation (e.g. DDX6, NONO and hnRNPM). Some of these host factors positively regulate DENV replication, whilst others are repressive (reviewed in Bidet and Garcia-Blanco, 2018). Identification of small molecules that influence activities of some of these host factors could be one way of modulating DENV replication.

4.8. Host proteins involved in DENV replication.

Several host pathways related to lipid metabolism (reviewed in Martin-Acebes et al., 2016; Krishnan and Garcia-Blanco, 2014), ER-golgi trafficking (Miller et al., 2018; Caputo et al., 2018), autophagy and unfolded protein response (Choi et al., 2018) have been shown to be important for DENV life cycle (during entry, replication and maturation) as well as for viral evasion from host immune response. Thus, besides direct anti-virals (NS5 NI, Balapiravir), DENV clinical trials encompassed inhibitors to host proteins (e..g. alpha-glycosidase inhibitors, Celgosivir and UV-4B) to effect DENV inhibition (reviewed in Low et al., 2018; Whitehorn et al., 2014). In the dearth of DAAs, researchers have focused on repurposing approved drugs that affect the above-mentioned host pathways for anti-DENV therapy (reviewed in Botta et al., 2018; Low et al., 2018; Lim et al., 2013a).

Increasingly, kinase inhibitors have been shown to impact DENV replication (Table 5, de Wispelaere et al., 2018, Smith et al., 2014; 2013; Clark et al., 2016; Chu and Yang, 2007). A recent report by Bekerman et al. (2017) revealed that DENV, HCV and Ebola virus exploit two kinases, AAK1 and GAK, that regulate host adaptor proteins AP1 and AP2, for entry and virus production. Treatment with two anti-cancer drugs, sunitinib and erlotinib, protected DENV-infected mice against morbidity and mortality (Pu et al., 2018; Bekerman et al., 2017). The

researchers subsequently synthesized highly specific GAK inhibitors that inhibited DENV replication, after optimising a isothiazolo[4,3□*b*]pyridine derivative from a small library screen against GAK (150 novel druglike compounds were tested in the KINOMEscan screening platform; Kovackova et al., 2015). The analogue with the best SI, **12r**, showed EC_{50}/CC_{50} values of 0.82/>25 μM and 3.54/>20 μM in Huh7 and human monocyte-derived dendritic cells, respectively (Pu et al., 2018b).

4.9. New host targets from omics approaches

With the advent of new technologies, additional mechanisms by which DENV engage host machinery continue to be elucidated. Proteomics, transcriptomics and genome-scale KO screens are powerful approaches to uncover host factors essential for DENV replication and pathogenesis, providing new candidate targets for antiviral drug development as well as potential biomarkers for prediction of disease severity.

Researchers have utlised different proteomic approaches such as yeast-two-hybrid assays, co-IP or tandem affinity purification followed by MS, stable isotope labeling by/with amino acids in cell culture (SILAC) to map interactions of DENV proteins (envelope, NS3, NS4B, NS5) within the viral RC and with host factors (reviewed in Gerold et al., 2017; Lum et al., 2016). Protein-protein interactions (PPIs) often have specific interfaces which may be targeted for therapeutic intervention. Of note, Karyal et al. (2016) mined all publicly available literature on dengue–human interactions into a searchable database called DenHunt ((http://proline.biochem.iisc.ernet.in/DenHunt/). A total of 682 direct interactions of human proteins with dengue viral components, 382 indirect interactions and 4120 differentially expressed human genes in dengue infected cell lines and patients were found. This collective information provides a rich resource for new anti-DENV strategies targeting host proteins. The

512 authors highlighted 20 host proteins that are critical for DENV replication and have been
513 commercially validated as drug targets.

514 Another comprehensive endeavour was conducted by Dey and Mukhopadhyay (2017)
515 who curated published papers as well as virus databases such as VirHostNet and VirusMentha, to
516 compile the free DenvInt database (https://denvint. 000webhostapp.com). The database lists
517 both dengue–human and dengue–mosquito protein interactions and will be updated montly to
518 incorporate new reports. As of 2017, the total Dengue–human PPI comprised 784 unique
519 interactions, including 535 non-redundant interactions between 335 different human proteins and
520 10 dengue proteins as well as 249 non-redundant interactions between 140 different mosquito
521 proteins and 10 dengue proteins. Amongst these, 535 dengue–human and 249 dengue–mosquito
522 interaction were studies conducted with DENV2 whilst only about 10 % of dengue-human PPI
523 were serotype independent.

524 Whilst target protein-protein interactions (PPI) may be challenging, drugs that target PPIs
525 are beginning to enter the market and a number of others are undergoing clinical trials (Scott et
526 al., 2016). Some examples of such marketed drugs are Tirofiban (an antiplatelet drug which
527 inhibits interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa; Hartzman et
528 al., 1992) and Lifitegrast (for dry eye treatment by inhibiting interaction between lymphocyte
529 function-associated antigen 1(LFA-1) and intercellular adhesion molecule 1 (ICAM-1); Tauber,
530 2015). Compounds in clinical trials include Idasanutlin (phase III trial; for anti-cancer
531 application by inhibit MDM2-p53 interaction; Ding et al., 2013) and AZD5991 (in phase I trials
532 for hematologic cancers by inhibiting interaction between Mcl-1 and Bak; Tron et al., 2018).

533 Transcriptomic approaches such as DNA microarrays have also enabled the dissection of
534 host genes that are altered by DENV infection as well as uncovered potential new biomarkers for
535 profiling disease severity ((Banerjee et al., 2017; Becker et al., 2015; Sun et al., 2013). More

536 recently, two independent genome-scale genetic KO screens determined that genes involved in
537 ER-translocation, protein degradation (ERAD), N-linked glycosylation were necessary for the
538 proper cleavage of the flavivirus structural proteins (prM and E) and secretion of viral particles
539 (reviewed in Puschnik et al., 2017). In particular, signal peptidase complex genes (SPCS-1, -2
540 and -3; Zhang et al., 2016), the oligosaccharyltransferase (OST) complex, and translocon-
541 associated protein (TRAP) complex (Marceau et al., 2016), were found to be important for
542 infectious virus production. These host genes could be investigated as targets for anti-DENV
543 therapy. As a proof-of-concept, the researchers used the oligosaccharyl-transferase inhibitor
544 NGI-1, to inhibit to DENV2 replication (EC_{50}/CC_{50} = 0.85/34.9 μM) and the other three DENV
545 serotypes (Puschnik et al., 2017).
546

547 **5. Challenges in the path to clinical development of dengue drugs**

548 The goal of the drug discovery process is to perform clinical studies to determine the
549 safety and efficacy of a drug, administered at a particular dose to a specific human target
550 population with acceptable risk /benefit ratios, as specified in the target product profile (TPP).
551 Ultimately, the aim is to achieve proof of safety (PoS), mechanism (PoM) and concept (PoC) for
552 the drug candidate whereby defined endpoints (measurables) are met and can be used to obtain
553 regulatory approval.

554 In the case of clinical development of dengue drugs, the trials conducted to-date use the
555 following parameters as primary measures of drug efficacy: (i) time to fever resolution,
556 resolution of or reduction in (ii) viremia, and (iii) NS1 antigenemia. However, none of these
557 trials have observed a significant difference in these measurables between drug-treated and
558 control groups (reviewed in Low et al., 2018). There are several considerations and challenges in
559 determining the efficacy of a dengue drug. Firstly, due to the rapid decline in viremia seen in

560 DENV patients, it is important to recruit DENV patients for clinical trials at very early stages of
561 infection in order to initiate dosing as early as possible. Yet, there is an absence of rapid and
562 sensitive POC diagnostics which can discriminate between dengue, and other endemic febrile-
563 causing illnesses (discussed in Section 2). Moreover, current DENV IgM/IgG immuno-assays
564 cannot differentiate between an individual with a secondary DENV infection, and a vaccinee
565 who has primary infection. This may pose problems when stratifying patients during late-stage
566 clinical trials to determine drug efficacy and to measure additional secondary endpoints (such as
567 progression to severe disease, or cytokine responses).

568 Secondly, DENV patients exhibit a wide variance in plasma virus levels during the
569 course of their illness. Reports indicate that in both DF and DHF patients, virus levels were
570 about 6-log different within the first 5 days of illness (4-10 $\log_{10}$ RNA copies/ml, Nguyen et al.,
571 2013; 2-9 $\log_{10}$ RNA copies/mL, Guidarde et al., 2008). On the other hand, at >5 days post-
572 illness, the difference was less pronounced (about 3-logs different) but levels were also
573 substantially lower (1-5 $\log_{10}$ RNA copies/ml; Guidarde et al., 2008). This large divergence in
574 virus titres can make it difficult to confirm if a drug candidate is effective when comparing the
575 treated and control arms. Thus careful segregation of the cohorts are needed, as has been done in
576 a some dengue trials conducted (Nguyuen et al., 2013).

577 Thirdly, whilst DENV is known to infect immune cells, it is not clear what additional cell
578 types or tissues are infected in the host, and how they contribute to viral pathogenesis and the
579 spectrum of dengue diseases. Failure to adequately deliver the drug candidate to all the relevant
580 human tissues or compartments in a timely fashion will compromise the efficacy of a drug
581 candidate. This uncertainty can also pose challenges for PK/PD modeling, dose regime design,
582 and determining the therapeutic index. Although current mouse models have been reported to
583 show some signatures of DENV disease (cytokine induction, thrombocytopenia, and systemic

584 infection), they do not fully recapitulate the full spectrum of dengue diseases and may not be
585 suitable for addressing this issue nor for PK/PD evaluation (Chan et al., 2015). Thus,
586 establishment of better predictive pre-clinical models, such as with non-human primates (Omatsu
587 et al., 2012, 2011; Onlmoon et al., 2010) will be advantageous. Ultimately, the use of human
588 challenge studies with DENV vaccine strains may be a way forward to profile clinical drug
589 candidates, post-phase I trials. In vitro, compound testing in a wide panel of cell types
590 (particularly in human primary cells) with different clinical DENV1-4 strains should be
591 conducted to build better dose-inhibition relationships.

592 Besides the lack of efficacy, lack of safety is another common cause of attrition during
593 drug development (Kola and Landis, 2004) and in clinical trials (Harrison, 2016). This latter
594 property is of particular concern in dengue drug development for several reasons: firstly,
595 majority of the target patient population in many South-east Asian countries are young children
596 (< 15 years old) and secondly, adult patients with severe DENV diseases often present with
597 comorbidities. Thirdly, differing physiology and immune status of patients with severe DENV
598 disease compared to those with mild, or intermediate DENV disease (See WHO Dengue
599 classification and levels of severity, 2009), may influence the PD/PK properties of the drug
600 candidate and hence, alter its safety and efficacy profiles. Hence, careful monitoring of drug
601 concentrations in DENV patients and patient stratification during clinical trials will most likely
602 be required to better understand efficacy outcomes (or lack thereof) and safety issues.

603 In general, drug-induced toxicities in liver, heart, kidney, and brain currently account for
604 more than 70% of drug attrition and withdrawal from the market (Wilke et al., 2007). Whilst
605 these may be mitigated by available in vitro safety profile panels (Supplementary Tables 3-5),
606 new in vitro techniques including cellular thermal shift assays (Molina and Nordlund, 2016;

607 Molina et al., 2013), and 3D organoids of liver, cardiac patch microtissues (Park et al., 2018) are
608 increasingly being utilized in the pharma industry to address safety concerns.
609

610 **6. Conclusions and Perspectives**

611 Intensive efforts from researchers in academia and industry have cumulated in significant
612 knowledge in the life cycle of DENV, its impact on the host and the consequent pathogenesis. A
613 large number of host targets are implicated in regulating the virus, some of which are
614 ubiquituous, whilst others are host (human, mosquito)- and cell-type specific. New technologies
615 that utilise "omics" approaches (proteomics, transcriptomics and genomics-scale knockout
616 screens) can provide holistic views of the interactomes between DENV and its host, and have
617 revealed new potential targets (e.g. OST complex) for anti-DENV drug development. This
618 expands the opportunity to repurpose other known drugs, such as metformin (Htun et al., 2018,
619 Sofo-Acosta et al., 2017) besides ivermectin, Celgosivir, lovastatin, or HCV inhibitors, for
620 DENV therapy.

621 Targeting host factors offer the advantages of a significantly higher barrier to emergence of
622 resistance (compared with DAA), due to absence of genetic pathways to resistance as well as
623 pan-antiviral activities. It may also permit the inhibition of related members of the viral genus or
624 family due to conserved pathways in the virus life cycles. Its drawback is the potential of
625 undesirable drug-induced side effects, which may be off- and/or on-target (arising from its
626 physiological function) in nature. As severe dengue diseases significantly impact host
627 physiology, targeting particular classes of host proteins may promote additional unpredicted
628 side-effects and will require close patient monitoring. This also calls for in-depth biological
629 understanding of the mechanism of action of the target gene in cells, in healthy and disease
630 settings, such as using iPSCs, human tissue biobanks and conducting genome editing studies.

631 Nevertheless, since dengue viruses cause acute diseases, these challenges should be
632 surmountable (previously mentioned in Lim et al., 2013a).

633 Increasingly, targeting PPIs is gaining success in different therapeutic areas, including in
634 infectious diseases, due to better knowledge about the druggability of the interfaces and better
635 screening methodologies (reviewed in Voter and Keck, 2018). New commercial focused
636 chemical libraries that have been designed specifically for PPI screening have also been
637 generated with the aim to overcome limitations of traditional compound libraries (e.g. from
638 Asinex, Chemdiv, Enamine). Thus, screening for inhibitors that block PPIs between DENV
639 proteins or between DENV and host proteins could be a new endeavour for the identification of
640 novel DENV inhibitors.

641 For phenotypic screens, DENV whole virus infection assays and DENV subgenomic
642 replicon cells have yielded interesting hits to both viral and host proteins. NS4B inhibitors are
643 the most frequent DAAs identified from screening efforts with different diverse compound
644 libraries. Despite dissimilarity in compound structures, some inhibitor classes (JNJ-1A,
645 2DM25N, NITD-618) share virus resistance phenotypes, suggesting that they target the same
646 region in DENV2 NS4B. Due to differences in DENV1-4 NS4B amino acid sequences, not all
647 NS4B inhibitors exhibit pan-serotype inhibition. As researchers have mainly used DENV2 (in
648 particular, with NGC strain) for phenotypic screens, conducting screens with other DENV
649 serotypes may generate additional new chemical scaffolds for NS4B, or other DENV protein
650 targets.

651 Development of NS4B inhibitors have been hampered by unfavourable PK properties (due
652 to low solubility and stability). Whilst medicinal chemistry is focused on improving
653 physicochemical characteristics (i.e. adherence to Lipinski's Rule of 5), increasing evidence
654 point to success in developing drugs that fall beyond the rule of 5 (bRo5). These include HCV

NS5A and NS3/4A protease inhibitors, and HIV-1 protease inhibitor, ritonavir. Understanding drug development in the bRo5 space has provided some guidance to optimize cell permeability and solubility, to achieve oral bioavailability for compounds with MW>500 (reviewed in Poongavanam et al., 2018). This may be the way forward for DENV NS4B inhibitors. With continued efforts, it is highly plausible that orally available DENV NS4B inhibitors can be achieved, as shown by promising efforts in the optimization of acyl-indole derivatives (Bardiot et al., 2018).

Amongst DENV enzymatic activities, NS5 RdRp is the most attractive drug target and also plausibly, the most feasible, based on experiences in anti-HCV and -HIV-1 drug approaches. A significant effort was undertaken at NITD to find NS5 RdRp inhibitors. Whilst the previous NI, NITD008 suffered from toxicity issues (Yin et al., 2009), incorporating counter assays in the NI progression flowchart (Wang et al., 2018; Jin et al., 2017; Feng et al., 2016) can help to mitigate this problem. Few amenable NS5 RdRp and MTase hits have been identified from biochemical and phenotypic screens (reviewed in Lim et al., 2015). This may be due to the absence of relevant chemical scaffolds in the libraries, and suggests that new chemical libraries may be required to uncover starting points to these two enzyme activities. On the other hand, developing DENV NS5 NNIs may, like NS4B inhibitors, fall into the category of bRo5 compounds, which necessitate strong medicinal chemistry and PK support. To date, one of the most potent DENV NS5 NNIs belong to the class of N-pocket inhibitors which were derived from FBS by X-ray crystallography (reviewed in Lim et al., 2018). This holds promise in the application of FBS as a suitable hit-finding strategy for DENV protein targets.

Researchers typically employ DENV infection assays with immortalised cell lines. The drawback is that these cells are genetically and metabolically altered. DENV is a complex disease, whereby disease outcome is strongly influenced by the host response. Thus, the use of

679 physiologically relevant cells, such as PBMCs from acutely infected patients or convalescent
680 DENV patients, for compound screening, may provide new chemical entities and insights on
681 DENV-host cell interaction. Applying alternate methods for assay readout (e.g. cytokine
682 production, markers of immune cell activation as surrogate markers for anti-DENV response)
683 may also reveal novel findings. Notably, DENV patients frequently exhibit leukopenia, making it
684 difficult to obtain sufficient quantities of PBMCs for large scale compound or genetic screens.
685 To circumvent this issue, induced pluripotent stem cells (iPSCs) may be generated from somatic
686 cells from symptomatic DENV patients (stratified according to disease severity), and
687 subsequently expanded and re-differentiated to immune cells for drug screening purposes or to
688 study virus pathogenesis. The availability of cells may also enable explorations into the use of
689 organoid differentiation, organ-on-chips, to model and study DENV disease.

690 The use of disease-relevant cell-types from patient-derived iPSCs have been successfully
691 applied in the fields of genetic and neurodegenerative diseases (Elitt et al., 2018; Hung et al.,
692 2017). Recently, human pluripotent stem cell (hPSC)-derived hepatocyte-like cells (HLCs) have
693 been demonstrated to support the complete ZIKV replication cycle and the virus is inhibited by
694 7-deaza-2'-C-methyladenosine (Tricot et al., 2018). Significant differences in the innate immune
695 response against ZIKV and antiviral drug sensitivity were observed when comparing hPSC-
696 HLCs and hepatoma cells.

697 DENV is the most important arthropod-borne viral disease in the world. In the last 20
698 years, anti-DENV drug discovery activities have yielded diverse hits against both viral and host
699 factors. Nevertheless, a number of hits, especially those derived from in silico docking exercises
700 from academic researchers, were not verified in DENV biochemical or cell-based assays. As
701 well, some hits identified from compound library screens are not fully characterized, perhaps due
702 to insufficient expertise in specific techniques or medicinal chemistry support. In some instances,

703 hits identified from biochemical screens with DENV enzymes were not confirmed by
704 biophysical or binding assays whilst DENV cell-active inhibitors are not checked for on-target
705 inhibition within cells. Thus potential inhibitors lanquish in the hit-finding phase, and are not
706 pursued further for medicinal chemistry interrogation. The creation of an open-source database
707 for all reported anti-DENV hits would enable researchers to review and re-visit interesting hits.
708 In this regard, the proposal to have a DENV drug/vaccine consortium made up of private-
709 public partnerships (PPP; Morales and van Loock 2018), would enable researchers to
710 collaborate, share resources and expertise, and to consolidate activities required for hit and lead
711 characterisation. This can help to advance global DENV drug discovery efforts in a concerted
712 fashion. An effective PPP will hopefully, draw greater medicinal chemistry expertise to appraise
713 promising hits and conduct lead optimisation exercises. On this note, the collection of a set of
714 validated (such as NS3 protease and NS4B inhibitors, NITD008, NS5 RdRp N-pocket inhibitors)
715 and unvalidated compounds from anti-DENV screens, curated by a central respository, could be
716 a useful tool-box to researchers who are conducting new screening exercises for DENV or other
717 related Flaviviruses. Such compound collections have been generated for malaria and
718 successfully applied to drug discovery in other neglected tropical diseases (Duffy et al., 2017;
719 van Voorhis et al., 2016).
720 The formation of a virtual research organization dedicated to DENV drug discovery, which
721 operates in an open-access format, can allow researchers to tap into an international network of
722 expertise from both academia and industry. Besides benefiting the DENV drug discovery
723 community, it can likely boost drug discovery efforts on other emerging flavi- and non-flavi-
724 viruses and enable rapid response in emergency outbreaks. Importantly, DENV patients will also
725 be better served by such an initiative. Key stakeholders for a successful PPP are (i) public-
726 sponsored organizations: governments, government sponsored organizations (e.g. CDC, NIH,

Pasteur Institute, INFECT-ERA), international health organizations (e.g. WHO, TDR) and academia (e.g. Centre for Drug Design and Discovery (CD3) at the University of Leuven, Belgium) (ii) for-profit: pharmaceutical industry, biotechnology companies (iii) not-for-profit and philanthropic organizations (e.g. Gates foundation, Welcome Trust, DNDi, GHIT).

Given that DENV affects more than 140 countries worldwide, there is a strong vested interest in the governments of these countries to join forces to combat this disease. For this to come to fruition, strong leadership and committment from the afore mentioned stakeholders are needed. To note, WHO, through the Special Programme for Research and Training in Tropical Diseases (TDR), is exploring the possibility to host a pooled fund, raised by the WHO, to support R&D for diseases primarily affecting low-to-middle-income countries (LMICs; type I-III diseases). This fund is intended to support a Scientific Working Group (SWG) to establish disease target product profiles (TPPs) and manage R&D project portfolios to accelerate the development of diagnostics, vaccines and treatments for these diseases, through transparent, efficient, non-political governance (WHO, TDR, 2016). Under WHO classification, DENV is a type II disease, and therapeutic explorations for combating DENV could be hosted under this framework.

Acknowledgements

I thank ex-colleagues who worked on dengue drug discovery at the Novartis Institute for Tropical Diseases (Singapore), Novartis Institute for Biomedical Research (Basel, CH; Cambridge, USA; Emeryville, USA), and the Genomics Institute of the Novartis Research Foundation (San Diego, USA), as well as ex-collaborators (Julien Lescar, Nanyang Technological University, Singapore; Gottfried Otting, Australian National University, Canberra, Australia) for invaluable discussions and insights.

751

752 **References**

753 1. Acosta, E.G., Kumar, A., Bartenschlager, R., 2014. Revisiting dengue virus-host cell
754 interaction: new insights into molecular and cellular virology. Adv Virus Res. 88, 1-109.
755 2. Ahmad, T., Yin, P., Saffitz, J., Pockros, P.J., Lalezari, J., Shiffman, M., Freilich, B.,
756 Zamparo, J., Brown, K., Dimitrova, D., Kumar, M., Manion, D., Heath-Chiozzi, M., Wolf,
757 R., Hughes, E., Muir, A.J., Hernandez, A.F., 2015. Cardiac dysfunction associated with a
758 nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 62, 409-16.
759 3. Alexander, H.K., Bonhoeffer, S., 2012. Pre-existence and emergence of drug resistance in a
760 generalized model of intra-host viral dynamics. Epidemics. 4,187-202.
761 4. Apte-Sengupta, S., Sirohi, D., Kuhn, R.J., 2014. Coupling of replication and assembly in
762 flaviviruses. Curr Opin Virol. 9, 134-42.
763 5. Arnold, J.J., Sharma, S.D., Feng, J.Y., Ray, A.S., Smidansky, E.D., Kireeva, M.L., Cho,
764 A., Perry, J., Vela, J.E., Park, Y., Xu, Y., Tian, Y., Babusis, D., Barauskus, O., Peterson,
765 B.R., Gnatt, A., Kashlev, M., Zhong, W., Cameron, C.E., 2012a. Sensitivity of
766 mitochondrial transcription and resistance of RNA polymerase II dependent nuclear
767 transcription to antiviral ribonucleosides. PLoS Pathog. 8, e1003030.
768 6. Arnold, J.J., Smidansky, E.D., Moustafa, I.M., Cameron, C.E., 2012b. Human
769 mitochondrial RNA polymerase: structure-function, mechanism and inhibition. Biochim
770 Biophys Acta. 1819, 948-60.
771 7. Bardiot, D., Koukni, M., Smets, W., Carlens, G., Kaptein, S., Dallmeier, K., Chaltin, P.,
772 Neyts, J., Marchand, A., 2018. Discovery of Indole Derivatives as Novel and Potent
773 Dengue Virus Inhibitors. J Med Chem. 61, 8390-8401.

8. Barral, K., Sallamand, C., Petzold, C., Coutard, B., Collet, A., Thillier, Y., Zimmermann, J., Vasseur, J.J., Canard, B., Rohayem, J, Debart, F., Decroly, E., 2013. Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening. Antiviral Res. 292-300.

9. Barrows, N.J., Campos, R.K., Liao, K.C., Prasanth, K.R., Soto-Acosta, R., Yeh, S.C., Schott-Lerner, G., Pompon, J., Sessions, O.M., Bradrick, S.S., Garcia-Blanco, M.A., 2018. Biochemistry and Molecular Biology of Flaviviruses. Chem Rev. 118, 4448-4482.

10. Balasubramanian, A., Manzano, M., Teramoto, T., Pilankatta, R., Padmanabhan, R., 2016. High throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antivir Res. 134, 6–16.

11. Banerjee, A., Shukla, S., Pandey, A.D., Goswami, S., Bandyopadhyay, B., Ramachandran, V., Das, S., Malhotra, A., Agarwal, A., Adhikari, S., Rahman, M., Chatterjee, S., Bhattacharya, N., Basu, N., Pandey, P., Sood, V., Vrati, S., 2017. RNA-Seq analysis of peripheral blood mononuclear cells reveals unique transcriptional signatures associated with disease progression in dengue patients. Transl Res. 186, 62-78.e9.

12. Basavannacharya, C., Vasudevan, S.G., 2014. Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format. Biochem Biophys Res Commun. 453, 539-44.

13. Becker, M., De Bastiani, M.A., Parisi, M.M., Guma, F.T., Markoski, M.M., Castro, M.A., Kaplan, M.H., Barbé-Tuana, F.M., Klamt, F., 2015. Integrated Transcriptomics Establish Macrophage Polarization Signatures and have Potential Applications for Clinical Health and Disease. Sci Rep. 5, 13351.

14. Beesetti, H., Tyagi, P., Medapi, B., Krishna, V.S., Sriram, D., Khanna, N., Swaminathan, S., 2018. A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells. Antivir Ther. 23, 385-394.

15. Bekerman, E., Neveu, G., Shulla, A., Brannan, J., Pu, S.Y., Wang, S., Xiao, F., Barouch-Bentov, R., Bakken, R.R., Mateo, R., Govero, J., Nagamine, C.M., Diamond, M.S., De Jonghe, S., Herdewijn, P., Dye, J.M., Randall, G., Einav, S., 2017. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 127,1338-1352.

16. Behnam, M.A., Graf, D., Bartenschlager, R., Zlotos, D.P., Klein, C.D., 2015. Discovery of nanomolar dengue and West Nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue. J Med Chem. 58, 9354–9370.

17. Benarroch, D., Selisko, B., Locatelli, G.A., Maga, G., Romette, J.L., Canard, B., 2004. The RNA helicase, nucleotide 5'-triphosphatase, and RNA 5'-triphosphatase activities of Dengue virus protein NS3 are Mg2+-dependent and require a functional Walker B motif in the helicase catalytic core. Virology. 328, 208-18.

18. Benmansour, F., Trist, I., Coutard, B., Decroly, E., Querat, G., Brancale, A., Barral., K., 2017. Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design. Europ J Med Chem. 125, 865-880.

19. Benmansour, F., Eydoux, C., Querat, G., de Lamballerie, X., Canard, B., Alvarez, K., Guillemot, J.C., Barral, K., 2016. Novel 2-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,3,4-oxadiazole and 3-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,2,4-oxadiazole derivatives as dengue virus inhibitors targeting NS5 polymerase Eur J Med Chem., 109, 146-156.

20. Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., Drake, J.M., Brownstein, J.S., Hoen, A.G., Sankoh, O., Myers, M.F., George, D.B., Jaenisch, T.,

820 Wint, G.R., Simmons, C.P., Scott, T.W., Farrar, J.J., Hay, S.I., 2013. The global
821 distribution and burden of dengue. Nature 496, 504-507.
822 21. Bidet, K., Gracia-Blanco, M.A., 2018. Flaviviral RNA Structures and Their Role
823 in Replication and Immunity. Adv Exp Med Biol. 1062, 45-62.
824 22. Bohnert, T., Gan, LS., 2013. Plasma protein binding: from discovery to development. J
825 Pharm Sci. 102, 2953-94.
826 23. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., Hirth, P., 2012.
827 "Vemurafenib: the first drug approved for BRAF-mutant cancer". Nat Rev Drug Discov.
828 11, 873–86.
829 24. Bollati, M., Alvarez, K., Assenberg, R., Baronti, C., Canard, B., Cook, S., Coutard, B.,
830 Decroly, E., de Lamballerie, X., Gould, E.A., Grard, G., Grimes, J.M., Hilgenfeld, R.,
831 Jansson, A.M., Malet, H., Mancini, E.J., Mastrangelo, E., Mattevi, A., Milani, M.,
832 Moureau, G., Neyts, J., Owens, R.J., Ren, J., Selisko, B., Speroni, S., Steuber, H., Stuart,
833 D.I., Unge, T., Bolognesi, M., 2010. Structure and functionality in flavivirus NS-proteins:
834 perspectives for drug design. Antiviral Res. 87, 125-148.
835 25. Botta, L., Rivara, M., Zuliani, V., Radi, M., 2018. Drug repurposing approaches to fight
836 Dengue virus infection and related diseases. Front Biosci (Landmark Ed). 23, 997-1019.
837 26. Brady, O.J., Gething, P.W., Bhatt, S., Messina, J.P., Brownstein, J.S., Hoen, A.G. et al.,
838 2012. Refining the global spatial limits of dengue virus transmission by evidence-based
839 consensus. PLoS Negl Trop Dis. 6, e1760.
840 27. Brown, J.A., Pack, L. R., Fowler, J.D., Suo, Z., 2011. Pre-steady-state kinetic analysis of
841 the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family
842 DNA polymerases. Antimicrob Agents Chemother. 55, 276–283.

28. Brumme CJ, Poon AFY., 2017. Promises and pitfalls of Illumina sequencing for HIV resistance genotyping. Virus Res. 239, 97-105.

29. Byrd, C.M., Dai, D., Grosenbach, D.W., Berhanu, A., Jones, K.F., Cardwell, K.B., Schneider, C., Wineinger, K.A., Page, J.M., Harver, C., Stavale, E., Tyavanagimatt, S., Stone, M.A., Bartenschlager, R., Scaturro, P., Hruby, D.E., Jordan, R., 2013a. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother 57, 15-25.

30. Byrd, C.M., Grosenbach, D.W., Berhanu, A., Dai, D., Jones, K.F., Cardwell, K.B., Schneider, C., Yang, G., Tyavanagimatt, S., Harver, C., Wineinger, K.A., Page, J., Stavale, E., Stone, M.A., Fuller, K.P., Lovejoy, C., Leeds, J.M., Hruby, D.E., Jordan, R., 2013b. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother. 57, 1902-1912.

31. Cabarcas-Montalvo, M., Maldonado-Rojas, W., Montes-Grajales, D., Bertel-Sevilla, A., Wagner-Döbler, I., Sztajer, H., Reck, M., Flechas-Alarcon, M., Ocazionez, R., Olivero-Verbel, J., 2016. Discovery of antiviral molecules for dengue: In silico search and biological evaluation. Eur J Med Chem. 110, 87-97.

32. Cannalire, R., Tarantino, D., Astolfi, A., Barreca, M.L., Sabatini, S., Massari, S., Tabarrini, O., Milani, M., Querat, G., Mastrangelo, E., Manfroni, G., Cecchetti, V., 2018. Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. Eur J Med Chem. 143, 1667-1676.

33. Caputo, A.T., Alonzi, D.S., Kiappes, J.L., Struwe, W.B., Cross, A., Basu, S., Darlot, B., Roversi, P., Zitzmann, N., 2018. Structural Insights into the Broad-Spectrum Antiviral Target Endoplasmic Reticulum Alpha-Glucosidase II. Adv Exp Med Biol. 1062, 265-276.

34. Carocci, M., Hinshaw, S.M., Rodgers, M.A., Villareal, V.A., Burri, D.J., Pilankatta, R., Maharaj, N.P., Gack, M.U., Stavale, E.J., Warfield, K.L., Yang, P.L., 2015. The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. Antimicrob Agents Chemother. 59, 85-95.

35. Castro C, Arnold, J.J., Cameron, C.E., 2005. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res 107, 141-149.

36. Chambers, T.J., Hahn, C.S., Galler, R., Rice, C.M., 1990. Flavivirus genome organization, expression and replication. Annu Rev Microbiol. 44, 649-88.

37. Chan, K.W, Watanabe, S., Kavishna, R., Alonso, S., Vasudevan, S.G., 2015. Animal models for studying dengue pathogenesis and therapy. Antiviral Res. 123, 5-14.

38. Chao, L.H., Jang, J., Johnson, A., Nguyen, A., Gray, N.S., Yang, P.L., Harrison, S.C., 2018. How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. Elife. 7, pii: e36461.

39. Chatel-Chaix, L., Bartenschlager, R., 2014. Dengue virus- and hepatitis C virus-induced replication and assembly compartments: the enemy inside--caught in the web. J Virol. 88, 5907-5911.

40. Chatelain, G., Debing, Y., De Burghgraeve, T., Zmurko, J., Saudi, M., Rozenski, J., Neyts, J., Van Aerschot, A., 2013. In search of flavivirus inhibitors: evaluation of different tritylated nucleoside analogues. Eur J Med Chem. 65, 249-55.

41. Chew, M.F., Poh, K.S., Poh, C.L., 2017. Peptides as Therapeutic Agents for Dengue Virus. Int J Med Sci. 14, 1342-1359.

42. Chen, Y., Yokokawa, F., Shi., P-Y., 2015. The search for nucleoside/nucleotide analog inhibitors of dengue virus. Anti-viral Res. 122, 12-19.

43. Choi, Y., Bowman, J.W., Jung, J.U., 2018. Autophagy during viral infection- a double-edged sword. Nat Reviews Microbiol. 16, 341-354.

44. Chu, J..J., Yang, P.L., 2007. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc Natl Acad Sci U S A. 104, 3520-5.

45. Chung, S.J., Krishnan, P.U., Leo, Y.S., 2015. Two Cases of False-Positive Dengue Non-Structural Protein 1 (NS1) Antigen in Patients with Hematological Malignancies and a Review of the Literature on the Use of NS1 for the Detection of Dengue Infection. Am. J. Trop. Med. Hyg. 92, 367–369

46. Chung, K.Y., Dong, H., Chao, A.T., Shi, P.Y., Lescar, J., Lim, S.P., 2010. Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2'-O methyltransferase activity in dengue virus. Virology 402, 52-60.

47. Clark, M.J., Miduturu, C., Schmidt, A.G., Zhu, X., Pitts, J.D., Wang, J., Potisopon, S., Zhang, J., Wojciechowski, A., Hann Chu J.J., Gray, N.S., Yang, P.L., 2016. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol. 23, 443-52.

48. Clas, S.D., Sanchez, R.I., Nofsinger, R., 2014. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. Drug Discov Today. 19, 79-87.

49. Copeland, R.A., 2016. The drug–target residence time model: a 10□year retrospective. Nat Rev Drug Discov. 15, 87-95.

50. Crouchet, E., Wrensch, F., Schuster, C., Zeisel, M.B., Baumert, T.F., 2018. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol. 11, 1–15.

51. de Wispelaere, M., Lian, W., Potisopon S., Li, P.C., Jang, J., Ficarro, S.B., Clark, M.J., Zhu, X., Kaplan, J.B., Pitts, J.D., Wales, T.E., Wang, J., Engen, J.R., Marto, J.A., Gray,

N.S., Yang, P.L., 2018. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem Biol. 25, 1006-1016.e8.

52. De Burghgraeve, T., Selisko, B., Kaptein, S., Chatelain, G., Leyssen, P., Debing, Y., Jacobs, M., Van Aerschot, A., Canard, B., Neyts, J., 2013. 3',5'Di-O-trityluridine inhibits in vitro flavivirus replication. Antiviral Res. 98, 242-7

53. de Wispelaere, M., LaCroix, A.J., Yang, P.L., 2013 The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol. 87, 7367-81.

54. Dey L., Mukhopadhyay A., 2017. DenvInt: A database of protein-protein interactions between dengue virus and its hosts. PLoS Negl Trop Dis. 11(10):e0005879.

55. Di, L., Kerns, E.H., Carter, G.T., 2009. Drug-like property concepts in pharmaceutical design. Curr Pharm Des. 15, 2184-94.

56. Diamond, M.S., Pierson, T.C., 2015. Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. Cell. 162, 488-92.

57. Ding, Q., Zhang, Z., Liu, J.J., Jiang, N., Zhang, J., Ross, T.M., Chu, X.J., Bartkovitz, D., Podlaski, F., Janson, C., Tovar, C., Filipovic, Z.M., Higgins, B., Glenn, K., Packman, K., Vassilev, L.T., Graves, B., 2013. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 56, 5979-5983

58. Domingo, E., Sheldon, J., Perales, C., 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev. 76, 159-216.

59. Drusano, G.L., Moore, K.P., Kleim, J.P., Prince, W., Bye, A., 2002. Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation. Antimicrob. Agents Chem. 46, 913-916.

60. Duffy, S., Sykes, M.L., Jones, A.J., Shelper, T.B., Simpson, M., Lang, R., Poulsen, S.A., Sleebs, B.E., Avery, V.M., 2017. Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. Antimicrob Agents Chemother. 61, Pii, e00379-17.

61. Einberg, P.A., Fischler, B., 2018. Successful antiviral therapy in patients with chronic hepatitis C virus infection and severe associated disease. Acta Paediatr. In press.

62. Erbel, P., Schiering, N., D'Arcy, A., Renatus, M., Kroemer, M., Lim, S., Yin, Z., Keller, T., Vasudevan, S., Hommel, U., 2006. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13, 372-373.

63. Erlanson, D.A., Fesik, S.W., Hubbard, R.E., Jahnke, W., Jhoti, H., 2016. Twenty years on: The impact of fragments on drug discovery. Nature Reviews Drug Discovery. 15, 605-619.

64. Faustino, A.F., Martins, I.C., Carvalho, F.A,, Castanho, M.A., Maurer-Stroh, S., Santos, N.C., 2015a. Understanding Dengue Virus Capsid Protein Interaction with Key Biological Targets. 5, 10592.

65. Faustino, A.F., Guerra, G.M., Huber, R.G., Hollmann, A., Domingues, M.M., Barbosa, G.M., Enguita, F.J., Bond, P.J., Castanho, M.A., Da Poian, A.T., Almeida, F.C., Santos, N.C., Martins, I.C., 2015b. Understanding dengue virus capsid protein disordered N-Terminus and pep14-23-based inhibition. ACS Chem Biol. 10, 517-26.

66. Faustino, A.F., Carvalho, F.A., Martins, I.C., Castanho, M.A., Mohana-Borges, R., Almeida, F.C., Da Poian, A.T., Santos, N.C., 2014 Dengue virus capsid protein interacts specifically with very low-density lipoproteins. Nanomedicine. 10, 247-55.

67. Fenaux, M., Lin, X., Yokokawa, F., Sweeney, Z., Saunders, O., Xie, L., Lim, S.P., Uteng, M., Uehara, K., Warne, R., Gang, W., Jones, C., Yendluri, S., Gu, H., Mansfield, K., Boisclair, J., Heimbach, T., Catoire, A., Bracken, K., Weaver, M., Moser, H., Zhong, W.,

2016. Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk. Antimicrob Agents Chemother. 60, 7077–7085.

68. Feng, J.Y., 2018. Addressing the selectivity and toxicity of antiviral nucleosides. Antivir Chem Chemother. 26, 2040206618758524.

69. Feng, J.Y., Xu, Y., Barauskas, O., Perry, J.K., Ahmadyar, S., Stepan, G., Yu, H., Babusis, D., Park, Y., McCutcheon, K., Perron, M., Schultz, B.E., Sakowicz, R., Ray, A.S., 2016. Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus. Antimicrob Agents Chemother 60, 806–817.

70. Fischer, M.A., Smith, J.L., Shum, D., Stein, D.A., Parkins, C., Bhinder, B., Radu, C., Hirsch, A.J., Djaballah, H., Nelson, J.A., Fruh, K., 2013. Flaviviruses are sensitive to inhibition of thymidine synthesis pathways J. Virol., 87, 9411-9419.

71. Fraser, J.E., Watanabe, S., Wang, C., Chan, W.K., Maher, B., Lopez-Denman, A., Hick, C., Wagstaff, K.M., Mackenzie, J.M., Sexton, P.M., Vasudevan, S.G., Jans, D.A., 2014. A nuclear transport inhibitor that modulates the unfolded protein response and provides *in vivo* protection against lethal dengue virus infection. J Infect Dis, 210, 1780–1791.

72. Gao, M., Nettles, R., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O'Boyle, D.R., 2nd, Lemm, J.A., Wang, C., Knipe, J.O., Chien, C., Colonno, R.J., Grasela, D.M., Meanwell, N.A., Hamann, L.G., 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 465, 96–100.

73. Galiano, V., Garcia-Valtanen, P., Micol, V., Encinar, J.A., 2016. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach. Drug Des Dev Ther. 10, 3163–3181.

985 74. Gerold, G., Bruening, J., Weigel, B., Pietschmann, T., 2017. Protein Interactions during the
986 Flavivirus and Hepacivirus Life Cycle. Mol Cell Proteomics. 16, S75-S91.
987 75. Goncalves, A., Peeling, R.W., Chu, M.C., Gubler, D.J., de Silva, A.M., Harris, E., Murtagh,
988 M., Chua, A., Rodriguez, W., Kelly, C., Wilder-Smith, A., 2018. Innovative and New
989 Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report. J Infect Dis.
990 217, 1060-1068.
991 76. Graci, J.D., Cameron, C.E., 2006. Mechanisms of action of ribavirin against distinct
992 viruses. Rev Med Virol. 16, 37–48.
993 77. Guedj, J., Neumann, A.U., 2010. Understanding hepatitis C viral dynamics with direct-
994 acting antiviral agents due to the interplay between intracellular replication and cellular
995 infection dynamics. J Theor Biol. 267, 330-40.
996 78. Guilarde, A.O., Turchi, M.D., Siqueira, J.B. Jr., Feres, V.C., Rocha, B., Levi, J.E., Souza,
997 V.A., Boas, L.S., Pannuti, C.S., Martelli, C.M., 2008. Dengue and dengue hemorrhagic
998 fever among adults: clinical outcomes related to viremia, serotypes, and antibody response.
999 J Infect Dis. 197, 817-24.
1000 79. Halstead, S.B., 2018. Safety issues from a Phase 3 clinical trial of a live-attenuated
1001 chimeric yellow fever tetravalent dengue vaccine Human Vaccines & Immunotherapeutics.
1002 1-5.
1003 80. Halstead,S., 200.8 Dengue Virus–Mosquito Interactions Annual Review of Entomology 53,
1004 273-291.
1005 81. Harrison, R.K., 2016. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov.15,
1006 817–818.
1007 82. Hartman, G.D., Egbertson, M.S., Halczenko, W., Laswell, W.L., Duggan, M.E., Smith,
1008 R.L., Naylor, A.M., Manno, P.D., Lynch, R.J., Zhang, G., Chang, C. T.-C., Gould, R.J.,

1009 1992. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite
1010 Inhibitors. J Med Chem 35, 4640–4642.
1011 83. Hernandez-Morales, I., Van Loock, M., 2018. An Industry Perspective on Dengue Drug
1012 Discovery and Development. Adv Exp Med Biol. 1062, 333-353.
1013 84. Hernandez-Morales, I., Geluykens, P., Clynhens, M., Strijbos, R., Goethals, O., Megens, S.,
1014 Verheyen, N., Last, S., McGowan, D., Coesemans, E., De Boeck, B., Stoops, B.,
1015 Devogelaere, B., Pauwels, F., Vandyck, K., Berke, J.M., Raboisson, P., Simmen, K., Lory,
1016 P., Van Loock, M., 2017. Characterization of a dengue NS4B inhibitor originating from an
1017 HCV small molecule library. Antiviral Res. 147, 149-158.
1018 85. Holmes, E.C., Twiddy, S.S., 2003. The origin, emergence and evolutionary genetics of
1019 dengue virus. Infect Genet Evol. 3, 19-28.
1020 86. Htun, H.L., Yeo, T.W., Tam, C.C., Pang, J., Leo, Y.S., Lye, D.C., 2018. Metformin Use
1021 and Severe Dengue in Diabetic Adults. Sci Rep. 8, 3344.
1022 87. Institute for Health Metrics and Evaluation (IHME). Global Health Data Exchange (GHDx)
1023 [Internet]. GBD Results Tool. 2017 [cited 2017 Jun 21].
1024 http://www.healthdata.org/institute-health-metrics-and-evaluation.
1025 88. Jin, Z., Kinkade, A., Behera, I., Chaudhuri, S., Tucker, K., Dyatkina, N., Rajwanshi, V.K.,
1026 Wang, G., Jekle, A,, Smith, D.B., Beigelman, L., Symons, J.A., Deval, J., 2017. Structure-
1027 activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside
1028 analogs. Antiviral Res. 143, 1–43.
1029 89. Jin, Z., Deval, J., Johnson, K.A., Swinney, D.C., 2011. Characterization of the elongation
1030 complex of dengue virus RNA polymerase: assembly, kinetics of nucleotide incorporation,
1031 and fidelity. J Biol Chem. 286, 2067–2077.

90. John, D.V., Lin, Y.S., Perng, G.C., 2015. Biomarkers of severe dengue disease - a review. J Biomed Sci. 14, 22:83.

91. Johnson, A.A., Ray, A.S., Hanes, J., Suo, Z., Colacino, J.M., Anderson, K.S., Johnson, K.A., 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 276, 40847–40857.

92. Karyala, P., Metri, R., Bathula, C., Yelamanchi, S.K., Sahoo, L., Arjunan, S., Sastri, N.P., Chandra, N., 2016. DenHunt - A Comprehensive Database of the Intricate Network of Dengue-Human Interactions. PLoS Negl Trop Dis. 10, e0004965.

93. Keller, T.H., Chen, Y.L., Knox, J.E., Lim, S.P., Ma, N.L., Patel, S.J., Sampath, A., Wang, Q.Y., Yin, Z., Vasudevan, S.G., 2006. Finding new medicines for flaviviral targets. Novartis Found Symp. 2006; 277.

94. Koczor, C.A., Torres, R.A., Lewis, W., 2012. The role of transporters in the toxicity of nucleoside and nucleotide analogs. Expert Opin Drug Metab Toxicol. 8, 665-76.

95. Koh-Stenta, X., Joy, J., Wang, S.F., Kwek, P.Z., Wee, J.L., Wan, K.F., Gayen, S., Chen, A.S., Kang, C., Lee, M.A., Poulsen, A., Vasudevan, S.G., Hill, J., Nacro, K., 2015. Identification of covalent active site inhibitors of dengue virus protease. Drug Des Devel Ther 9, 6389–6399.

96. Kohler, J.J., Nettles, J.H., Amblard, F., Hurwitz, S.J., Bassit, L., Stanton, R.A., Ehteshami, M., Schinazi, R.F., 2014. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist. 5, 7:41-56.

97. Kola, I. and Landis, J., 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716.

98. Kovackova, S., Chang, L., Bekerman, E., Neveu, G., BarouchBentov, R., Chaikuad, A., Heroven, C., Šála, M., De Jonghe, S., Knapp, S., Einav, S., Herdewijn, P., 2015. Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti- Hepatitis C Agents. J Med Chem. 58, 3393−3410.

99. Krishnan, M.N., Garcia-Blanco, M.A., 2014. Targeting host factors to treat West Nile and Dengue viral infections. Virus 6, 683–708.

100. Leal, E.S., Aucar, M.G., Gebhard, L.G., Iglesias, N.G., Pascual, M.J., Casal, J.J., Gamarnik, A.V., Cavasotto, C.N., Bollini, M., 2017. Discovery of novel dengue virus entry inhibitors via a structure-based approach. Bioorg Med Chem Lett. 27, 3851-3855.

101. Lee, J.C., Tseng, C.K., Wu, Y.H., Kaushik-Basu, N., Lin, C.K., Chen, W.C., Wu, H.N., 2015. Characterization of the activity of 2'-C methylcytidine against dengue virus replication. Antiviral Res. 116, 1-9.

102. Leonel, C.A., Lima, W.G., Dos Santos, M., Ferraz, A.C., Taranto, A.G., de Magalhães, J.C., Dos Santos, L.L., Ferreira, J.M.S., 2018. Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds. Arch Virol. 163, 575-586.

103. Lescar, J., Soh, S., Lee, L.T., Vasudevan, S.G., Kang, C., Lim, S.P., 2018. The Dengue Virus Replication Complex: From RNA Replication to Protein-Protein Interactions to Evasion of Innate Immunity. Adv Exp Med Biol. 1062, 115-129.

104. Leung, D., Schroder, K., White, H., Fang, N.X., Stoermer, M.J., Abbenante, G., Martin, J.L., Young, P.R., Fairlie, D.P., 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem. 76, 45762-71.

105. Leung, P., Eltahla, A.A., Lloyd, A.R., Bull, R.A., Luciani, F., 2017. Understanding the complex evolution of rapidly mutating viruses with deep sequencing: Beyond the analysis of viral diversity. Virus Res. 239, 43-54.

106. Li, G.H., Ning, Z.J., Liu, Y.M., Li, X.H., 2017. Neurological Manifestations of Dengue Infection. Front Cell Infect Microbiol. 25, 7:449.

107. Li, J., Lim, S.P., Beer, D., Patel, V., Wen, D., Tumanut, C., Tully, D.C., Williams, J.A., Jiricek, J., Priestle, J.P., Harris, J.L., Vasudevan, S.G., 2005. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem. 280, 28766-28774.

108. Li L., Basavannacharya, C., Chan, K.W., Shang, L., Vasudevan, S.G., Yin, Z., 2015. Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease. Chem Biol Drug Des. 86, 255-64.

109. Lian, W., Jang, J., Potisopon, S., Li, P.C., Rahmeh, A., Wang, J., Kwiatkowski, N.P., Gray, N.S., Yang, P.L., 2018. Discovery of Immunologically Inspired Small Molecules that Target the Viral Envelope Protein. ACS Infect Dis. 4, 1395-1406.

110. Liang, Z., Wu, S., Li, Y., He, L., Wu, M., Jiang, L., Feng, L., Zhang, P., Huang, X., 2011. Activation of toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-beta in cultured hepatoma cells. PLoS One 6, e23346.

111. Libraty, D.H., Endy, T.P., Houng, H.S., Green, S., Kalayanarooj, S., Suntayakorn, S., Chansiriwongs, W., Vaughn, D.W., Nisalak, A., Ennis, F.A., Rothman, A.L., 2002a. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. 185, 1213-1221.

112. Libraty, D.H., Young, P.R., Pickering, D., Endy, T.P., Kalayanarooj, S., Green, S., Vaughn, D.W., Nisalak, A., Ennis, F.A., Rothman, A.L., 2002b. High circulating levels of the

1102 dengue virus nonstructural protein NS1 early in dengue illness correlate with the
1103 development of dengue hemorrhagic fever. J Infect Dis. 186, 1165-1168.
1104 113. Lim, S.P., Noble, C.G., Nilar, S., Shi, P.Y., Yokokawa, F., 2018. Adv Exp Med Biol. 1062,
1105 187-198.
1106 114. Lim, S.P., Noble, C.G., Seh, C.C., Soh, T.S., El Sahili, A., Chan, G.K., Lescar, J., Arora,
1107 R., Benson, T., Nilar, S., Manjunatha, U., Wan, K.F., Dong, H., Xie, X., Shi, P.Y.,
1108 Yokokawa, F., 2016. Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors:
1109 Mechanism of Action and Resistance Profiling. PLoS Pathog 12, e1005737.
1110 115. Lim, S.P., Noble, C.G., Shi, P.Y., 2015. The dengue virus NS5 protein as a target for drug
1111 discovery. Antiviral Res. 119, 57-67.
1112 116. Lim, S.P., Wang, Q-Y., Noble, C.G., Chen, Y-L., Dong, H., Zou, B., Yokokawa, F., Nilar,
1113 S., Smith, P., Beer, D., Lescar, J., Shi, P.Y., 2013a. Ten years of dengue drug discovery:
1114 progress and prospects. Antivir Res. 100, 500–519.
1115 117. Lim, S.P., Bodenreider, C., Shi, P.Y., 2013b. Detection and quantification of flavivirus NS5
1116 methyl-transferase activities. Methods Mol Biol. 1030, 249-68.
1117 118. Lim, S.P., Sonntag, L.S., Noble, C., Nilar, S.H., Ng, R.H., Zou, G., Monaghan, P., Chung,
1118 K.Y., Dong, H., Liu, B., Bodenreider, C., Lee, G., Ding, M., Chan, W.L., Wang, G., Jian,
1119 Y.L., Chao, A.T., Lescar, J., Yin, Z., Vedananda, T.R., Keller, T.H., Shi, P.Y., 2011. Small
1120 molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem 286,
1121 6233-6240.
1122 119. Lim, S.P., Wen, D., Yap, T.L., Yan, C.K., Lescar, J., Vasudevan, S.G., 2008. A scintillation
1123 proximity assay for dengue virus NS5 2'-O-methyltransferase-kinetic and inhibition
1124 analyses. Antiviral Res 80, 360-369.

120. Lin, K.H., Ali, A., Rusere, L., Soumana, D.I., Kurt Yilmaz. N., Schiffer, C.A., 2017. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side. J Virol. 91, e00045-17

121. Lin, K.H., Nalivaika, E.A., Prachanronarong, K.L., Yilmaz, N.K., Schiffer, C.A., 2016. Dengue protease substrate recognition: binding of the prime side. ACS Infect Dis. 2, 734-743.

122. Lindenbach, B.D., Thiel, H.-J., Rice, C.M., 2007. Flaviviridae: The Virus and Their Replication, p. 1101-1152. In D.M. Knipe and P.M. Howley (ed), Fields virology, 5th., vol. 1. Lippincott William & Wilkins, Philadelphia, Pa.

123. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 23, 3-25.

124. Liu, H., Wu, R., Sun, Y., Ye, Y., Chen, J., Luo, X., Shen, X., Liu, H., 2014. Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease. Bioorg Med Chem. 22, 6344-52.

125. Liu, X., Chen, C., Hop, C.E., 2011. Do we need to optimize plasma protein and tissue binding in drug discovery? Curr Top Med Chem. 11, 450-66.

126. Low, J.G., Gatsinga, R., Vasudeva, S.G., Sampath, A., 2018. Adv Exp Med Biol. 1062, 319-332.

127. Lu, D., Liu, J., Zhang, Y., Liu, F., Zeng, L., Peng, R., Yang, L., Ying, H., Tang, W., Chen, W., Zuo, J., Tong, X., Liu, T., Hu, Y., 2018. Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors. Eur J Med Chem. 145, 328-337.

128. Lu, H., Tonge, P.J., 2010. Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol. 14, 467-74.

129. Lum, K. K., and Cristea, I.M., 2016. Proteomic approaches to uncovering virus-host protein interactions during the progression of viral infection. Expert Rev. Proteomics 13, 325–340.

130. Lund, K.C., Wallace, K.B., 2004. Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovasc Toxicol. 4, 217-28.

131. Luo, D., Vasudevan, S.G., Lescar, J., 2015. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antiviral Res. 118, 148-58.

132. Lynx, M.D, McKee, E.E., 2006. 3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 72, 239–243.

133. Marceau, C.D., Puschnik, A.S., Majzoub, K., Ooi, Y.S., Brewer, S.M., Fuchs, G., Swaminathan, K., Mata, M.A., Elias, J.E., Sarnow, P., Carette, J.E., 2016 A Small-Molecule Oligosaccharyltransferase Inhibitor with Pan-flaviviral Activity. Nature. 535, 159-63.

134. Martins, I.C., Gomes-Neto, F., Faustino, A.F., Carvalho, F.A., Carneiro, F.A., Bozza, P.T., Mohana-Borges., R., Castanho, M.A., Almeida, F.C., Santos, N.C., Da Poian, A.T., 2012. The disordered N-terminal region of dengue virus capsid protein contains a drug targetable lipid droplet-binding motif. Biochem J, 444, 405-415.

135. Martín-Acebes, M.A., Vázquez-Calvo, Á., Saiz, J.C., 2016. Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses. Prog Lipid Res. 64, 123-137.

136. Mathew, A., 2018. Regulation and Function of NK and T Cells During Dengue Virus Infection and Vaccination. Adv Exp Med Biol. 1062, 251-264.

137. Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de Lamballerie, X., Neyts, J., Hanson, A.M., Frick, D.N., Bolognesi, M., Milani, M., 2012. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 67, 1884-94.

138. Miller, J.L., Tyrell, B.E., Ziitzmann, N., 2018. Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus. Adv Exp Med Biol. 1062, 277-301.

139. Mislak, A.C., Anderson, K.S., 2015. Insights into the molecular mechanism of polymerization and nucleoside reverse transcriptase inhibitor incorporation by human PrimPol. Antimicrob. Agents Chemother. 60, 561–569.

140. Molina, M., Nordlund., P., 2015. The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies. Annu Rev Pharmacol Toxicol. 56, 141-161.

141. Molina, M., Jafari , R., Ignatushchenko, M., Seki, T., Larsson, E.A., Dan, C., Sreekumar, L., Cao, Y., Nordlund, P., 2013. Monitoring drug target engagement in cells and tissues using the cellular thermalshift assay. Science. 341, 84-87.

142. Morison, J., Rathore, A.P.S., Mantri, C.K., Aman, S.A.B., Nishida, A., St. John, A.L., 2017. Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. J Virol. 91, pii: e00617-17.

143. Nasirudeen, A.M., Wong, H.H., Thien, P., Xu, S., Lam, K.P., Liu, D.X., 2011. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis. 5, e926.

144. Ndjomou, J., Kolli, R., Mukherjee, S., Shadrick, W. R., Hanson, A. M., Sweeney, N. L., Bartczak, D., Li, K., Frankowski, K. J., Schoenen, F. J., and Frick, D. N., 2012. Fluorescent

primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation. Antiviral Res. 96, 245− 255.

145. Ng, C.Y., Gu, F., Phong, W.Y., Chen, Y.L., Lim, S.P., Davidson, A., Vasudevan, S.G., 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76, 222-231.

146. Nguyen, N.M., Tran, C.N., Phung, L.K., Duong, K.T., Huynh Hle, A., Farrar, J., Nguyen, Q.T., Tran, H.T., Nguyen, C.V., Merson, L., Hoang, L.T., Hibberd, M.L., Aw, P.P., Wilm, A., Nagarajan, N., Nguyen, D.T., Pham, M.P., Nguyen, T.T., Javanbakht, H., Klumpp, K., Hammond, J., Petric, R., Wolbers, M., Nguyen, C.T., Simmons, C.P., 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 207, 1442-1450.

147. Nhi, D.M., Huy, N.T., Ohyama, K., Kimura, D., Lan, N.T., Uchida, L., Thuong, N.V., Nhon, C.T., Phuc le, H., Mai, N.T., Mizukami, S., Bao, L.Q., Doan, N.N., Binh, N.V., Quang, L.C., Karbwang, J., Yui, K., Morita, K., Huong, V.T., Hirayama, K., 2016. A Proteomic Approach Identifies Candidate Early Biomarkers to Predict Severe Dengue in Children. PLoS Negl Trop Dis. 10, e0004435.

148. Nitsche, C., 2018. Strategies Towards Protease Inhibitors for Emerging Flaviviruses. Advances in Experimental Medicine and Biology 1062, 175-186.

149. Nitsche, C., Zhang, L., Weigel, L.F., Schilz, J., Graf, D., Bartenschlager, R., Hilgenfeld, R., Klein, C.D., 2017. Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology. J Med Chem. 60, 511-516.

150. Niyomrattanakit, P., Wan, K.F., Chung, K.Y., Abas, S.N., Seh, C.C., Dong, H., Lim, C.C., Chao, A.T., Lee, C.B., Nilar, S., Lescar, J., Shi, P.Y., Beer, D., Lim, S.P., 2015.

Stabilization of dengue virus polymerase in de novo initiation assay provides advantages for compound screening. Antiviral Res. 119, 36-46.

151. Niyomrattanakit, P., Abas, S.N., Lim, C.C., Beer, D., Shi, P.Y., Chen, Y.L., 2011. A fluorescence-based alkaline phosphatase-coupled polymerase assay for identification of inhibitors of dengue virus RNA-dependent RNA polymerase. J Biomol Screen. 16, 201–210.

152. Niyomrattanakit, P., Chen, Y.L., Dong, H., Yin, Z., Qing, M., Glickman, J.F., Lin, K., Mueller, D., Voshol, H., Lim, J.Y., Nilar, S., Keller, T.H., Shi, P.Y., 2010. Inhibition of dengue virus polymerase by blocking of the RNA tunnel. J Virol 84, 5678-5686.

153. Noble, C.G., Lim, S.P., Arora, R., Yokokawa, F., Nilar, S., Seh, C.C., Wright, S.K., Benson, T.E., Smith, P.W., Shi, P.Y., 2016. A Conserved Pocket in the Dengue Virus Polymerase Identified through Fragment-based Screening. J Biol Chem. 291, 8541-8.

154. Noble, C.G., Lim, S.P., Chen, Y.L., Liew, C.W., Yap, L., Lescar, J., Shi, P.Y., 2013. Conformational flexibility of the dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor. J Virol. 87, 5291–5295.

155. Noble, C.G., Chen, Y.L., Dong, H., Gu, F., Lim, S.P., Schul, W., Wang, Q.Y., Shi, P.Y., 2010. Strategies for development of Dengue virus inhibitors. Antiviral Res 85, 450-462.

156. Nomaguchi, M., Ackermann, M., Yon, C., You, S., Padmanabhan, R., 2003. De novo synthesis of negative-strand RNA by Dengue virus RNA-dependent RNA polymerase in vitro: nucleotide, primer, and template parameters. J Virol. 77, 8831-42.

157. Neufeldt, C.J., Cortese, M., Acosta, E.G., Bartenschlager, R., 2018. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 16, 125-142.

158. Olsen, D.B., Eldrup, A.B., Bartholomew, L., Bhat, B., Bosserman, M.R., Ceccacci, A., Colwell, L.F., Fay, J.F., Flores, O.A., Getty, K.L., Grobler, J.A., Lafemina, R.L., Markel,

E.J., Migliaccio, G., Prhavc, M., Stahlhut, M.W., Tomassini, J.E., Maccoss, M., Hazuda, D.J., Carroll, S.S., 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother. 48, 3944–3953.

159. Omatsu, T., Moi, M.L., Takasaki, T., Nakamura, S., Katakai, Y., Tajima, S., Ito, M., Yoshida, T., Saito, A., Akari, H., Kurane, I., 2012. Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus. J Med Primatol. 41, 289-296.

160. Omatsu, T., Moi, M.L., Hirayama, T., Takasaki, T., Nakamura, S., Tajima, S., Ito, M., Yoshida, T., Saito, A., Katakai, Y., Akari, H., Kurane, I., 2011. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol. 92, 2272-2280.

161. Onlamoon, N., Noisakran, S., Hsiao, H.M., Duncan, A., Villinger, F., Ansari, A.A., Perng, G.C., 2010. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood. 115, 1823-34.

162. Paixão, E.S., Teixeira, M.G., Rodrigues, L.C., 2018. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. BMJ Glob Health. 3, e000530.

163. Pałasz, A., Cież, D., 2015. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications. Eur J Med Chem. 97, 582-611.

164. Pambudi, S., Kawashita, N., Phanthanawiboon, S., Omokoko, M.D., Masrinoul, P., Yamashita, A., Limkittikul, K., Yasunaga, T., Takagi, T., Ikuta, K., Kurosu, T., 2013. A small compound targeting the interaction between nonstructural proteins 2B and 3 inhibits dengue virus replication. Biochem Biophys Res Commun. 440, 393-8.

165. Pan American Health Organization, Tool for the Diagnosis and Care of Patients with Suspected Arboviral Diseases. March-2017. http://iris.paho.org/xmlui/handle/123456789/33895

166. Park, J., Wetzel, I., Dreau, D., Cho, H., 2018. 3D Miniaturization of Human Organs for Drug Discovery. Adv Healthc Mater. In press.

167. Pelliccia, S., Wu, Y.H., Coluccia, A., La Regina, G., Tseng, C.K., Famiglini, V., Masci, D., Hiscott, J., Lee, J.C., Silvestri, R., 2017. Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities. J Enzyme Inhib Med Chem. 32, 1091-1101.

168. Perera, N., Miller, J.L., Zitzmann, N., 2017. The role of the unfolded protein response in dengue virus pathogenesis. Cell Microbiol. 19, 5.

169. Pinto A.K., Brien, J.D., Lam, C.Y., Johnson, S., Chiang, C., Hiscott, J., Sarathy, V.V., Barrett, A.D., Shretsa, S., Diamond, M.S., 2016. Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio. 6, e01316-15.

170. Poongavanam, V., Doak, B.C., Kihlberg, J., 2018. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. Curr Opin Chem Biol. 44, 23-29.

171. Potisopon, S., Ferron, F., Fattorini, V., Selisko, B., Canard B., 2017. Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2′-modified nucleotide analogues. Anti-viral Res. 140, 25-36.

172. Powers, C.N., Setzer, W.N., 2016. An In-Silico investigation of phytochemicals as antiviral agents against dengue fever. Comb. Chem. High Throughput Screen. 19, 516–53.

1289 173. Prachanronarong, K.L., Özen, A., Thayer, K.M., Yilmaz, L.S., Zeldovich, K.B., Bolon,
1290 D.N., Kowalik, T.F., Jensen, J.D., Finberg, R.W., Wang, J.P., Kurt-Yilmaz, N., Schiffer,
1291 C.A., 2016. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1
1292 and N2 Neuraminidase.J Chem Theory Comput. 12, 6098-6108
1293 174. Pryke, K.M., Abraham, J., Sali, T.M., Gall, B.J., Archer, I., Liu, A., Bambina, S., Baird, J.,
1294 Gough, M., Chakhtoura, M., Haddad, E.K., Kirby, I.T., Nilsen, A., Streblow, D.N., Hirsch,
1295 A.J., Smith, J.L., DeFilippis, V.R., 2017. A Novel Agonist of the TRIF Pathway Induces a
1296 Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. MBio.
1297 8, e00452-17.
1298 175. Pu, S.Y., Xiao, F., Schor, S., Bekerman, E., Zanini, F., Barouch-Bentov, R., Nagamine,
1299 C.M., Einav, S., 2018a. Feasibility and biological rationale of repurposing sunitinib and
1300 erlotinib for dengue treatment. Antiviral Res. 155, 67-75.
1301 176. Pu, S.Y., Wouters, R., Schor, S., Rozenski, J., Barouch-Bentov, R., Prugar, L.I., O'Brien,
1302 C.M., Brannan, J.M., Dye, J.M., Herdewijn, P., De Jonghe, S., Einav, S., 2018b.
1303 Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated
1304 Kinase (GAK) with Broad-Spectrum Antiviral Activity. J Med Chem. 61, 6178-6192.
1305 177. Puschnik, A.S., Marceau, C.D., Ooi, Y.S., Majzoub, K., Rinis, N., Contessa, J.N., Carette,
1306 J.E., 2017. A Small-Molecule Oligosaccharyltransferase Inhibitor with Pan-flaviviral
1307 Activity. Cell Rep. 21, 3032-3039.
1308 178. Rausch, K., Hackett, B.A., Weinbren, N.L., Reeder, S,M., Sadovsky, Y., Hunter, C.A.,
1309 Schultz, D.C., Coyne, C.B., Cherry, S., 2017. Screening Bioactives Reveals
1310 Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus. Cell Rep. 18,
1311 804-815.

1312 179. Rivino, L., 2018. Understanding the Human T Cell Response to Dengue Virus. Adv Exp
1313 Med Biol. 1062, 241-250.
1314 180. Saroch, A., Arya, V., Sinha, N., Taneja, R.S., Sahai, P., Mahajan, R.K., 2017. Clinical and
1315 laboratory factors associated with mortality in dengue. Trop Doct. 47, 141-145.
1316 181. Saudi, M., Zmurko, J., Kaptein, S., Rozenski, J., Gadakh, B., Chaltin, P., Marchand, A.,
1317 Neyts, J., Van Aerschot, A., 2016. Synthetic strategy and antiviral evaluation of diamide
1318 containing heterocycles targeting dengue and yellow fever virus. Eur J Med Chem. 121,
1319 158-168.
1320 182. Saudi, M., Zmurko, J., Kaptein, S., Rozenski, J., Neyts, J., Van Aerschot, A., 2014a.
1321 Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting
1322 dengue and yellow fever virus. Eur J Med Chem. 87, 529-39.
1323 183. Saudi, M., Zmurko, J., Kaptein, S., Rozenski, J., Neyts, J., Van Aerschot, A., 2014b. In
1324 search of Flavivirus inhibitors part 2: tritylated, diphenylmethylated and other alkylated
1325 nucleoside analogues. Eur J Med Chem. 76, 98-109.
1326 184. Scaturro, P., Trist, I.M., Paul, D., Kumar, A., Acosta, E.G., Byrd, C.M., Jordan, R.,
1327 Brancale, A., Bartenschlager, R., 2014. Characterization of the mode of action of a potent
1328 dengue virus capsid inhibitor. J Virol. 88, 11540-55.
1329 185. Scheffold, A., Jebaraj, B.M.C., Stilgenbauer, S., 2018. Venetoclax: Targeting BCL2 in
1330 Hematological Cancers. Recent Results Cancer Res. 212, 215-242.
1331 186. Schmidt, A.G., Lee, K., Yang, P.L., Harrison, S.C., 2012. Small-molecule inhibitors of
1332 dengue-virus entry. 1406. PLoS Pathog 8, e1002627
1333 187. Schmidt, A.G., Yang, P.L., Harrison, S.C., 2010. Peptide inhibitors of flavivirus entry
1334 derived from the E protein stem. J Virol 84, 12549–12554.

188. Schul, W., Liu, W., Xu, H.Y., Flamand, M., Vasudevan, S.G., 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 195, 665-74.

189. Scott, D.E., Bayly, A.R., Abell, C., Skidmore, J., 2016. Small molecules, big targets: drug discovery faces the protein-proteininteraction challenge. Nat Rev Drug Discov. 15, 533-50.

190. Selisko, B., Dutartre, H., Guillemot, J.C., Debarnot, C., Benarroch, D., Khromykh, A., Desprès, P., Egloff, M.P., Canard, B., 2006. Comparative mechanistic studies of de novo RNA synthesis by flavivirus RNA-dependent RNA polymerases. Virology. 351, 145-58

191. Shepard, D.S., Undurraga, E.A., Halasa, Y.A., Stanaway, J.D., 2016. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis 16, 935–941.

192. Shum, D., Smith, J.L. Hirsch, A.J., Bhinder, B., Radu, C., Stein, D.A., Nelson, J.A., Fruh, K., Djaballah, H., 2010. High-content assay to identify inhibitors of dengue virus infection. Assay drug Dev. Technol., 8, 553-570.

193. Silva, J.V.J., Jr, Lopes, T.R.R., Oliveira-Filho, E.F., Oliveira, R.A.S., Durães-Carvalho, R., Gil, L.H.V.G., 2018. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. Acta Trop. 182, 257-263.

194. Sim, S., Hibbaerd, M., 2016. Genomic approaches for understanding dengue: insights from the virus, vector, and host. Genome Biol. 2, 17:38.

195. Simmons, C.P., McPherson, K., Van Vinh Chau, N., Hoai Tam, D.T., Young, P., Mackenzie, J., Wills, B., 2015. Recent advances in dengue pathogenesis and clinical management. Vaccine. 33, 7061-8.

196. Smith, J.L., Sheridan, K., Parkins, C.J., Frueh, L., Jemison, A.L., Strode, K., Dow, G., Nilsen, A., Hirsch, A.J., 2018. Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions. Antiviral Res. 155, 12-19.

197. Smith, R.L., Tan, J.M.E., Jonker, M.J., Jongejan, A., Buissink, T., Veldhuijzen, S., van Kampen, A.H.C., Brul, S., van der Spek, H., 2017. Beyond the polymerase-γ theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity. PLoS One. 12, e0187424.

198. Smith, J.L., Stein, D.A., Shum, D., Fischer, M.A., Radu, C., Bhinder, B., Djaballah, H., Nelson, J.A. Fruh, K. Hirsch, A.J., 2014a. Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. J. Virol. 88, 5533-5542.

199. Smith, T.M., Lim, S.P., Yue, K., Busby, S.A., Arora, R., Seh, C.C., Wright, S.K., Nutiu, R., Niyomrattanakit, P., Wan, K.F., Beer, D., Shi, P.Y., Benson, T.E., 2014b. Identifying initiation and elongation inhibitors of dengue virus RNA polymerase in a high-throughput lead-finding campaign. J Biomol Screen. 20, 153-63.

200. Soto-Acosta, R., Bautista-Carbajal, P., Cervantes-Salazar, M., Angel-Ambrocio, A.H., Del Angel, R.M., 2017. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. PLoS Pathog. 13, e1006257.

201. SOVALDI®, Sofosbuvir prescription sheet (Nov/2017), Gilead Sciences, Inc. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf

202. Stranix, B., Beaulieu, F., Bouchard, J-E., Milot, G., Wang, Z., Ruel, R., 2009. HIV integrase inhibitors from pyridoxine. US patent US8742123B2.

1382 203. Sun, P., García, J., Comach, G., Vahey, M.T., Wang, Z., Forshey, B.M., Morrison,
1383 A.C., Sierra, G., Bazan, I., Rocha, C., Vilcarromero, S., Blair, P.J., Scott, T.W., Camacho,
1384 D.E., Ockenhouse, C.F., Halsey, E.S., Kochel, T.J., 2013. Sequential waves of gene
1385 expression in patients with clinically defined dengueillnesses reveal subtle disease phases
1386 and predict disease severity. PLoS Negl Trop Dis. 7, e2298.
1387 204. Sweeney, N.L., Hanson, A.M, Mukherjee, S., Ndjomou, J., Geiss, B.J., Steel, J.J.,
1388 Frankowski, K.J., Li, K., Schoenen, F.J., Frick, D.N., 2015. Benzothiazole and Pyrrolone
1389 Flavivirus Inhibitors Targeting the Viral Helicase. ACS Infect Dis. 1, 140-148.
1390 205. Szymanski, M.R., Kuznetsov, V.B., Shumate, C., Meng, Q., Lee, Y.S., Patel, G., Patel, S.,
1391 Yin, Y.W., 2015. Structural basis for processivity and antiviral drug toxicity in human
1392 mitochondrial DNA replicase. EMBO J. 34, 1959-70.
1393 206. Tarantino, D., Cannalire, R., Mastrangelo, E., Croci, R., Querat, G., Barreca,
1394 M.L., Bolognesi, M., Manfroni, G., Cecchetti, V., Milani M., 2016. Targeting flavivirus
1395 RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor Antivir.
1396 Res., 134, 226-235.
1397 207. Tauber, J., 2015. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of
1398 Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology. **122**,
1399 2423–31.
1400 208. Tay, M.Y., Fraser, J.E., Chan, W.K., Moreland, N.J., Rathore, A.P., Wang, C., Vasudevan,
1401 S.G., Jans, D.A., 2013. Nuclear localization of dengue virus (DENV) 1-4 non-structural
1402 protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral
1403 Res. 99, 301-6.

209. Tomlinson, S,M.,Watowich, S.J., 2012 Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors. Antiviral Res. 93, 245-52.

210. Tomlinson, S.M., Watowich, S.J., 2011. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Antiviral Res. 89, 127-35.

211. Tomlinson, S.M., Malmstrom, R.D., Russo, A., Mueller, N., Pang, Y.P., Watowich, S.J., 2009. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res. 82, 110-4.

212. Tricot, T., Helsen, N., Kapstein, S.J.F., Neyts, J., Verfaille, C.M., 2018. Human stem cell-derived hepatocyte-like cells support Zika virus replication and provide a relevant model to assess the efficacy of potential antivirals. PLoS One. 13, e0209097.

213. Tron, A.E., Belmonte, M.A., Adam, A., Aquila, B.M., Boise, L.H., Chiarparin, E., Cidado, J., Embrey, K.J., Gangl, E., Gibbons, F.D., Gregory, G.P., Hargreaves, D., Hendricks, J.A., Johannes, J.W., Johnstone, R.W., Kazmirski, S.L., Kettle, J.G., Lamb, M.L., Matulis, S.M., Nooka, A.K., Packer, M.J., Peng, B., Rawlins, P.B., Robbins, D.W., Schuller, A.G., Su, N., Yang, W., Ye, Q., Zheng, X., Secrist, J.P., Clark, E.A., Wilson, D.M., Fawell, S.E., Hird, A.W., 2018. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 9, 5341.

214. van Cleef, K.W., Overheul, G.J., Thomassen, M.C., Kaptein, S.J., Davidson, A.D., Jacobs, M., Neyts, J., van Kuppeveld, F.J., van Rij, R.P., 2013. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res. 99, 165-71.

215. Van Voorhis, W.C. et al. 2016. Open Source Drug Discovery with the Malaria Box CompoundCollection for Neglected Diseases and Beyond. PLoS Pathog. 12, e1005763.

216. Velvadapu, V., Farmer, B.T., Reitz, A.B., 2015. Chapter 7 - Fragment-Based Drug Discovery. The Practice of Medicinal Chemistry, 4th Edition. Pages 161-180. Edited by Wermuth et al. Elservier Ltd.

217. Venkatesham, A., Saudi, M., Kaptein, S., Neyts, J., Rozenski, J., Froeyen, M., Van Aerschot, A., 2017. Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors. Eur J Med Chem. 126, 101-109.

218. Vermehren, J., Park, J.S., Jacobson, I., Zeuzem, S., 2018. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 10. Pii, S0168-8278(18)32181-0.

219. Vincetti, P., Caporuscio, F., Kaptein, S., Gioiello, A., Mancino, V., Suzuki, Y., Yamamoto, N., Crespan, E., Lossani, A., Maga, G., Rastelli, G., Castagnolo, D., Neyts, J., Leyssen, P., Costantino, G., Radi, M., 2015. Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. J Med Chem. 58, 4964-75.

220. Viswanathan, U., Tomlinson, S.M., Fonner, J.M., Mock, S.A., Watowich, S.J., 2014 Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal. J Chem Inf Model. 54, 2816-25

221. Voter, A.F., Keck, J.L., 2018. Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases. Adv Protein Chem Struct Biol. 111, 197-222.

1448 222.Wagstaff, K.M., Rawlinson, S.M., Hearps, A.C., Jans, D.A., 2011. An AlphaScreen(R)-
1449 based assay for high-throughput screening for specific inhibitors of nuclear import. J.
1450 Biomol. Screen. 16, 192-200.
1451 223.Wang, C.C., Huang, Z.S., Chiang, P.L., Chen, C.T., Wu, H.N., 2009. Analysis of the
1452 nucleoside triphosphatase, RNA triphosphatase, and unwinding activities of
1453 the helicase domain of dengue virus NS3 protein. FEBS Lett. 583, 691-6.
1454 224.Wang, G., Lim, S.P., Chen, Y.L., Hunziker, J., Rao, R., Gu, F., She, C.C., Ghafar, N.A.,
1455 Xu, H., Chan, K., Lin, X., Saunders, O.L., Fenaux, M., Zhong, W., Shi, P.Y., Yokokawa,
1456 F., 2018. Structure-activity relationship of uridine-based nucleoside phosphoramidate
1457 prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase. Bioorg Med
1458 Chem Lett. 28, 2324-2327.
1459 225.Wang, Q.Y., Dong, H., Zou, B., Karuna, R., Wan, K.F., Zou, J., Susila, A., Yip, A., Shan,
1460 C., Yeo, K.L., Xu, H., Ding, M., Chan, W.L., Gu, F., Seah, P.G., Liu, W., Lakshminarayana,
1461 S.B., Kang, C., Lescar, J., Blasco, F., Smith, P.W., Shi, P.Y., 2015. Discovery
1462 of Dengue Virus NS4B Inhibitors. J Virol. 89, 8233-44.
1463 226.Wang, Q.Y., Bushell, S., Qing, M., Xu, H.Y., Bonavia, A., Nunes, S., Zhou, J., Poh, M.K.,
1464 Florez de Sessions, P., Niyomrattanakit, P., Dong, H., Hoffmaster, K., Goh, A., Nilar, S.,
1465 Schul, W., Jones, S., Kramer, L., Compton, T., Shi, P.Y., 2011a. Inhibition of dengue virus
1466 through suppression of host pyrimidine biosynthesis. J Virol. 85, 6548-6556.
1467 227.Wang, Q.Y., Kondreddi, R.R., Xie, X., Rao, R., Nilar, S., Xu, H.Y., Qing, M., Chang, D.,
1468 Dong, H., Yokokawa, F., Lakshminarayana, S.B., Goh, A., Schul, W., Kramer, L., Keller,
1469 T.H., Shi, P.Y., 2011b. A translation inhibitor that suppresses dengue virus in vitro and in
1470 vivo. Antimicrob Agents Chemother. 55, 4072-4080.

1471 228. Weng, Z., Shao, X., Graf, D., Wang, C., Klein, C.D., Wang, J., Zhou, G.C., 2016.
1472 Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue
1473 virus-2 NS2B-NS3 protease inhibitors. Eur J Med Chem. 125, 751–759.
1474 229. Whitehorn, J., Yacoub, S., Anders, K.L., Macareo, L.R., Cassetti, M.C., Nguyen Van, V.C.,
1475 Shi, P.Y., Wills, B., Simmons, C.P., 2014. Dengue therapeutics, chemoprophylaxis, and
1476 allied tools: state of the art and future directions. PLoS Negl Trop Dis. 8, e3025
1477 230. WHO, Special Programme for Research and Training in Tropical Diseases (TDR), Health
1478 product research & development fund: a proposal for financing and operation, 2016.
1479 231. WHO, 2016-2018, Disease Outbreak news (DON) http://www.who.int/csr/don/en.
1480 232. WHO Fact sheet on dengue. http://www.who.int/en/news-room/fact-sheets/detail/dengue-
1481 and-severe-dengue.
1482 233. WHO, Global Strategy for dengue prevention and control, 2012-2020.
1483 234. WHO, WHO Technical 62 Report Series, Stability testing of active pharmaceutical
1484 ingredients and finished pharmaceutical products,
1485 http://www.who.int/medicines/areas/quality_safety/quality_assurance/StabilityAPIsandFPP
1486 S-QAS16-694Rev1-26072017.pdf
1487 235. WHO, Dengue guidelines for diagnosis, tretment, prevention and control, 2009.
1488 https://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf
1489 236. Wilke, R.A., Lin, D.W., Roden, D.M., Watkins, P.B., Flockhart, D., Zineh, I., Giacomini,
1490 K.M., Krauss, R.M., 2007. Identifying genetic risk factors for serious adverse drug
1491 reactions: current progress and challenges. Nat Rev Drug Discov. 6, 904-916.
1492 237. Xie, X., Zou, J., Wang, Q.Y., Shi, P.Y., 2015. Targeting dengue virus NS4B protein for
1493 drug discovery. Antiviral Res. 118, 39-45.

1494 238. Xu, H,T., Colby-Germinario, S.P., Hassounah, S.A., Fogarty, C., Osman, N., Palanisamy,
1495 N., Han, Y., Oliveira, M., Quan, Y., Wainberg, M.A., 2017. Evaluation of Sofosbuvir (β-D-
1496 2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication. Sci
1497 Rep. 7, 6345.
1498 239. Xu, H.T., Colby-Germinario, S.P., Hassounah, S., Quashie, P,K., Han, Y., Oliveira, M.,
1499 Stranix, B.R., Wainberg, M.A., 2016. Identification of a Pyridoxine-Derived Small-
1500 Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase.
1501 Antimicrob Agents Chemother. 60, 600-8.
1502 240. Yang, C.C., Hu, H.S., Wu, R.H., Wu, S.H., Lee, S.J., Jiaang, W.T., Chern, J.H., Huang,
1503 Z.S., Wu, H.N., Chang, C.M., Yueh, A., 2014. A novel dengue virus inhibitor, BP13944,
1504 discovered by high-throughput screening with dengue virus replicon cells selects for
1505 resistance in the viral NS2B/NS3 protease. Antimicrob Agents Chemother. 58, 110-9.
1506 241. Yang. C-C., Hsieh. Y-C., Lee. S-J., Wu, S.H., Liao, C.L., Tsao, C.H., Chao, Y.S., Chern,
1507 J.H., Wu, C.P., Yueh, A., 2011. Novel dengue virus specific NS2B/NS3 protease inhibitor,
1508 BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother.
1509 55, 229–238.
1510 242. Yao, X., Guo, S., Wu, W., Wang, J., Wu, S., He, S., Wan, H., Nandakumar, K.S., Chen, X,
1511 Ning, S., Zhu, Q., Liu, S., 2018. Q63, a novel DENV2 RdRp non-nucleoside inhibitor,
1512 inhibited DENV2 replication and infection. J. Pharm. Sci. 138, 247-256.
1513 243. Yildiz, M., Ghosh, S., Bell, J.A., Sherman, W., Hardy, J.A., 2013. Allosteric inhibition of
1514 the NS2B-NS3 protease from dengue virus. ACS Chem Biol. 8, 2744-52.
1515 244. Yilmaz, K.N., Swanstrom, R, Schiffer, C.A., 2016. Improving Viral Protease Inhibitors to
1516 Counter Drug Resistance. Trends Microbiol. 24, 547-557.

245. Yin, Z., Chen, Y.L., Kondreddi, R.R., Chan, W.L., Wang, G., Ng, R.H., Lim, J.Y., Lee, W.Y., Jeyaraj, D.A., Niyomrattanakit, P., Wen, D., Chao, A., Glickman, J.F., Voshol, H., Mueller, D., Spanka, C., Dressler, S., Nilar, S., Vasudevan, S.G., Shi, P.Y., Keller, T.H., 2009. N-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase. J Med Chem. 52, 7934-7.

246. Yokokawa, F., Nilar, S., Noble, C.G., Lim, S.P., Rao, R., Tania, S., Wang, G., Lee, G., Hunziker, J., Karuna, R., Manjunatha, U., Shi, P.Y., Smith, P.W., 2016. Discovery of potent non- nucleoside inhibitors of dengue viral RNA-dependent RNA polymerase from a fragment hit using structure- based drug design. J Med Chem 59, 3935–3952.

247. Young, M.J., 2017. Off-Target Effects of Drugs that Disrupt Human Mitochondrial DNA Maintenance. Front Mol Biosci. 4, 74.

248. Yusof, R., Clum, S., Wetzel, M., Murthy, H.M., Padmanabhan, R., 2000. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem. 275, 9963-9.

249. Zhang, R.,Miner, J.J., Gorman, M.J., Rausch, K., Ramage, H., White, J.P., Zuiani, A., Zhang, P., Fernandez, E., Zhang, Q., Dowd, K.A., Pierson, T.C., Cherry, S., Diamond, M.S., 2016. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature. 535, 164-8.

250. Zhou, G.C., Weng, Z., Shao, X., Liu, F., Nie, X., Liu, J., Wang, D., Wang, C., Guo, K., 2013. Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors. Bioorg Med Chem Lett. 23, 6549–6554

251. Zou, B., Chan, W.L., Ding, M., Leong, S.Y., Nilar, S., Seah, P.G., Liu, W., Karuna, R., Blasco, F., Yip, A., Chao, A., Susila, A., Dong, H., Wang, Q.Y., Xu, H.Y., Chan, K., Wan, K.F., Gu. F., Diagana, T.T., Wagner, T., Dix, I., Shi, P.Y., Smith, P.W., 2015. Lead

optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitors. ACS Med Chem Lett. 6, 344-8.

Figure legend.

Figure 1. Dengue virus life cycle. DENV infects host cells such as monocytes by first attaching to cell surface receptors, followed by cell entry via a clathrin-dependent entry pathway (Fig. 1). After fusion of the virus envelope with endosomal membrane, the viral RNA is released into the cytosol and translated on the rough endoplasmic reticulum (ER) membrane. Translated DENV non-structural proteins re-organize the ER membrane to form replicative complexes within double-membrane vesicles, where viral RNA replication and virus assembly is initiated. Reproduced with permission from Neufeldt et al., 2018.

Table 1. Compound screening with *in vitro* DENV enzyme assays

Inhibitors Type/Source	Library size	Screening Assay/Method	Most potent Inhibitor	DENV/Host Target	Reference
In-house library	2,000	in vitro DENV2 NS2B/3 protease assay; 384 well format	BT24 (quinoline derivative), IC_{50} = 5 μM; inhibits DENV1-4 in cell-based assays	DENV NS2B/3 protease; binding to an allosteric site near active site of DENV-2 protease analyzed by in silico docking; no biophysical or genetic validation to confirm specificity.	Beesetti et al., 2018
In-house library of HCV NS5B inhibitors	18	In vitro screening with Dengue 3 NS5 RdRp de novo initiation assay with ssRNA polyC template	compounds **8** and **10** (2,2-dioxido-2,1-benzothiazine benzoates derivatives) with IC_{50} of 0.6 and 0.9 μM; Compound **8** (non-competitive mode of inhibition), EC_{50}> 20 μM; proposed to bind to RdRp N-pocket by molecular modelling.	DENV3 NS5 RdRp; inhibitory specificity confirmed by DLS and Triton-X-100 addition in RdRp assay. No biophysical or genetic validation to confirm specificity.	Cannalire et al., 2018
Pyrazole analogs	Not stated	DENV NS5 de novo initiation FAPA assay with 3'UTR viral RNA	Compounds **1**-**3** (pyrazole derivatives): NS5 Pol de novo initiation IC_{50}= 6-8 μM, DENV2 cell-based RdRp and infection assays, EC_{50}= 6-12 μM; compound **3** (10 mg/kg) protected mice from lethal dose of intracerebrally injected DENV.	DENV NS5 RdRp; no biophysical or genetic validation to confirm specificity.	Pelliccia et al., 2017
in-house library	not stated	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Bz-Nle-Lys–Arg–Arg–MCA	Fused bicyclic derivatives of pyrrolidine and imidazolidinone, SAR conducted; compound **2** (DENV2 IC_{50}, K_i and EC_{50} = 1.2, 4.9 and 39.4 μM)	DENV NS2B/3 protease; binding in protease active site analyzed by in silico docking; no biophysical or genetic validation to confirm specificity.	Weng et al., 2017

		in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Bz-Nle-Lys–Arg–Arg–MCA	dipeptides of methionine–proline anilides, SAR conducted; compound **1** has DENV2 IC_{50}, K_i and EC_{50} = 1.2, 4.9 and 38.7 μM (competitive inhibitor)	DENV NS2B/3 protease; binding in protease active site analyzed by in silico docking; no biophysical or genetic validation to confirm specificity.	Weng et al., 2017; Zhou et al., 2013
Asinex, TimTec, Biomol, Enamine, Chembridge, ChemDiv, Life Chemicals, Maybridge, MicroSource, NIH, NINDS, Prestwick, Sigma LOPAC, ICBG Fungal Extracts	≤ 120,000	in vitro DENV2 NS2B/3 protease assay; 384 well format; fluorescent peptide substrate, Bz-Nle-Lys-Arg-Arg-AMC	29 hits chosen for reconfirmation; DENV2 K_i, EC_{50} and CC_{50} values of 8 selected compounds (A-H) ranged from 0.22 - 6.9 μM, 0.08 to >20 μM (plaque assays and replicon) and 29->100 μM.	DENV NS2B/3 protease; binding in protease active site analyzed by in silico docking; binding validated by competitive fluorescence quench assay with BPTI. No genetic validation.	Balasubramanian et al., 2016
French National Chemical Library	not stated	DENV2 NS5 RdRp de novo initiation assay with homopolymeric(U) RNA (picoGreen incorporation)	SAR conducted from hit, compound **1** (IC_{50} = 1.3 μM). Analogues **18**, **27**, **33** and **34** (3-phenyl-5-[(E)-2-(thiophen2-yl)ethenyl]-1,2,4-oxadiazole and 5-phenyl-2-[2-(2-thienyl)ethenyl]-1,3,4-oxadiazole derivatives), IC_{50} = 2-9 μM; EC_{50} from 2-12 μM; CC_{50} from 30->100 μM.	DENV2 NS5 RdRp; no biophysical or genetic validation to confirm specificity.	Benmansour et al., 2016
National Institutes of Health Molecular Libraries Small Molecule Repository	65,423	in vitro WNV NS2B/3 protease; fluorescent peptide substrate, Pyr-RTKR-AMC; 384 well format	compounds **1** and **2** (Pyrazole ester derivative), DENV IC_{50} = 8.5 and 0.5 μM	DENV NS2B/3 protease; binding validated by ESI-TOF MS and NMR with WT and S135A protease mutant, possibly via covalent interaction to active site; binding to DENV2 protease active site analyzed by in silico docking. No validation in DENV cell-based assays.	Koh-Stenta et al., 2015; Johnston et al., 2007.
focused helicase inhibitor library (ML283 analogues and other compounds)	253	DENV NS3 ATPase colorimetric assay with helicase domain in presence of poly(U)	HTS hit, ML283 (benzothiazole derivative); SAR conducted. Analogue **24** has DENV ATPase and helicase unwinding IC_{50} =500	DENV NS3 helicase/ATPase; no biophysical or genetic validation to confirm	Sweeney et al., 2015; Ndjomou et al., 2012

			nM and 1.5 μM; EC_{50} = 7.1 μM; SI = 17; active against HCV helicase. Second HTS hit class, pyrrolones; compounds b-**30** have weak DENV ATPase and cell-based activities, not active against HCV helicase.	specificity.	
In-house library	250	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Boc–Gly–Arg–Arg–AMC; binding assay based on microscale thermophoresis (MST) technology	Compound **6** (benzothiazole derivatives); DENV2, 3 NS2B/3 protease assay, IC_{50} = 4 and 1 μM respectively (noncompetitive inhibition); DENV2 EC_{50} = 0.8 μM; DENV2 protease cell-based assay EC_{50} = 3.2 μM.	DENV NS2B/3 protease; binding in allosteric site in protease analyzed by in silico docking; compound binding validated by MST; no genetic validation to confirm specificity.	Wu et al., 2015
Experimental Therapeutics Centre, Singapore	1600	In vitro fluorescent molecular beacon assay (DENV4 helicase unwinding activity); 384 well format	Suramin has K_i of 0.75 ± 0.03 μM (non-competitive inhibitor).	DENV NS3 helicase; no biophysical or genetic validation to confirm specificity.	Basavannacharyam and Vasudevan, 2014
Commercial (source not stated)	7000	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Bz-Nle-Lys-Arg-Arg-AMC	Hit, compound **1** (thiadiazolopyrimidine) has DENV2 IC_{50} = 6.1 μM. SAR conducted; compound **8b** (thiadiazoloacrylamide derivative) has DENV2 IC_{50} =2.24 μM	DENV NS2B/3 protease; binding in allosteric site in protease analyzed by in silico docking; compound binding validated by MST; no genetic validation.	Liu et al., 2014
Novartis	≤ 257,000	DENV4 NS5 RdRp (aa266-900) fluorescent de novo initiation FAPA and LCMS detection assays	Various chemical scaffolds, NS5 RdRp IC_{50} <20 μM, DENV2 replicon EC_{50} <30 μM	DENV4 NS5 RdRp; biophysical validation with DSF. No genetic validation to confirm specificity.	Smith et al., 2014b

MicroSource Spectrum Collection (MicroSource Discovery Systems Inc., Gaylordsville, CT)	2000	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Boc–Gly–Arg–Arg–AMC	Tyrothricin (DENV2 K_i = 12 μM; competitive inhibition); Ivermectin (DENV2 K_i = 79 μM; mixed non-competitive inhibition); Selamectin (DENV2 K_i = 15 μM; mixed non-competitive inhibition)	DENV NS2B/3 protease; counter-screens to remove artifacts; specificity checked with trypsin assay; no biophysical or genetic validation to confirm specificity.	Tomlinson and Watowich, 2012
crude venom extractions of cone snails (comprise disulfide-rich short peptides of 10−40 residues) followed by fractionation	not stated	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Bz-Nle-Lys-Arg-Arg-AMC	Initial hit, MrIA (conotoxin from marmoreus, 13-aa peptide), followed by SAR. Cyclic octapeptide, **9** has DENV2 NS2B/3 K_i = 9 and 2.2 μM, respectively	DENV NS2B/3 protease; binding in active site in protease analyzed by in silico docking; no biophysical or genetic validation to confirm specificity	Xu et al., 2012
Chemical Diversity Laboratory (San Diego, CA)	41,600	in vitro DENV2 NS2B/3 protease colorimetric assay; peptide substrate acetyl-TTSTRR-para-nitroaniline	BP2109 DENV2 IC_{50} of 15.43 μM, DENV-2 replicon EC_{50} = 0.17 μM.	DENV NS2B/3 protease; compound resistant DENV2 shows R55K and E80K mutations in NS2B; no biophysical validation.	Yang et al., 2011
Novartis	1 million	DENV4 NS5 Pol elongation SPA assay (homopolyC/oligoG)	primary hit, NITD-1 (IC_{50} =7.2 mM, N-sulfonylanthranilic acid derivative); SAR conducted. Most active analogue, NITD-28 (IC_{50} = 260 nM); inactive in DENV cell-based assays	DENV2 NS5 FL; binding confirmed by uv photo-crosslinking studies and MS analysis.	Niyomrattanakit et al., 2010; Yin et al., 2009

Table 2. Compound screening with DENV protein binding assays.

Inhibitors Type/Source	Library size	Screening Assay/Method	Inhibitor	DENV/Host Target	Reference
Selleck bioactive compound library and the Chemdiv 7 library	21,271	Alpha screen with DENV prefusion E dimer or domain I (DI)-DII protein and GNF-2 inhibitor (4,6-disubstituted pyrimidine derivative)	7 compounds, IC_{50} < 10 μM; DENV2 EC_{50} range from 0.8-9 μM	DENV Envelope; no validation of on-target inhibition in DENV-infected cells.	Lian et al 2018
Quinazolinone derivatives	not stated	SPR with DENV2 RdRp (aa272-900)	Q63, K_d = 0.9 μM; DENV-1, -2, -4 EC_{50} = 1.7–2.1 μM.	DENV NS5 RdRp; binding confirmed by ITC, binding site in RdRp analyzed by in silico docking. No validation of on-target inhibition in DENV-infected cells.	Yao et al., 2018
Maybridge Chemical Company; RO3 fragment library 2009 (Cambridge, U.K.)	500	Thermo-denaturation assay with DENV4 NS3 helicase and DENV3 NS5 MTase	No hits for helicase, 7 hits for MTase (IC_{50} range from 0.18-9 mM); fragment linking strategy improved 2'-*O* MTase inhibitory activity.	DENV NS3 helicase and NS5 MTase; binding site in MTase analyzed by in silico docking. No biophysical or genetic validation.	Benmansour et al., 2017; Coutard et al., 2014
Novartis in-house fragment library	1408	DENV3 RdRp (aa 273-900) X-ray crystallography	Most potent compounds, **27**, **29**, **29i**; DENV1-4 NS5 de novo initiation (dnI) IC_{50} = 13-172 nM; DENV4 NS5 elongation IC_{50} = 0.43-5 μM; DENV1-4 EC_{50} = 2-14 μM.	DENV NS5 RdRp; binding confirmed by ITC, SPR, DSF, cellular thermo-shift. Compound resistant DENV2 replicons have L512V and E802D mutations in RdRp.	Noble et al.,2016; Yokokawa et al., 2016; Lim et al., 2016
LOPAC (Library of Pharmacologically Active Compounds; Sigma, St. Louis, MO)	480	AlphaScreen® to inhibit interaction between HIV-1 integrase and nuclear transport receptor importin α/β1 (IMPα/β1)	Ivermectin; inhibition of DENV1/2 NS5- IMPα/β1 interaction, IC_{50} = 1.5-2.3 μM; EC_{50} = 1.6–2.3 μM.	DENV NS5-IMPα/β1 interaction; no validation of on-target inhibition in DENV-infected cells.	Tay et al., 2013; Wagstaff et al., 2011

Cysteine reactive probes	5	Binding of cysteine reactive probes to DENV NS2B/3 protease cysteine mutant A125C; fluorescent peptide substrate, N-acetyl-Gly-Arg-Arg-AMC	5,5'-dithiobis-(2-nitrobenzoic acid (DTNB) and biarylchloromethylketone (BAClMK)	DENV NS2B/3 protease; binding confirmed by X-ray crystallography.	Yildiz et al., 2013
NRSB library, Institute of Chemistry and Cell Biology Longwood Screening Facility, Harvard Medical School	235,456	DENV2 MTase GTP-bodipy displacement assay	Hit class with thioxothiazolidin core. 24 analogues tested. BG-323 has DENV2 guanylation K_i and IC_{50} = = 7.5 and7.3 μM; EC_{50} = 30 μM	DENV MTase; binding site in MTase analyzed by in silico docking; no validation of on-target inhibition in DENV-infected cells.	Stahla-Beek et al., 2012
Compound libraries at NSRB at Harvard Medical School.	≤ 30,000	DENV2 Env stem peptide (aa419–447) conjugated with FITC- soluble Env trimer FP assay ; 384 well format	1662G07 (Maybridge; IC_{50} = 15 μM; EC_{50}/CC_{50}= 16.9/>100 μM); and different analogues, IC_{50} = 8-40 μM; DENV2 EC_{50} = 1.5-10 μM	DENV Envelope; binding confirmed by SPR; no validation of on-target inhibition in DENV-infected cells.	Schmidt et al., 2012, 2010

Table 3. DENV rational drug design.

Inhibitors Type/Source	Library size	Screening Assay/Method	Inhibitor	DENV/Host Target	Reference
Cyclic peptides designed from aprotinin (target DENV protease prime sites)	19	Designs are based on aprotinin-bound DENV3 NS2B/3 protease X-ray structure (PDB code 3U1J). Fluorescence resonance energy transfer (FRET)-based NS2B/3 protease assay; ITC	19 cyclic peptides targeting S3 to S4' positions made and tested. CP7 (PC*RARIYGGC*A; cyclized through a disulfide bond between two cysteine residues*), DENV3 K_i= 2.9 μM	DENV NS2B/3 protease; molecular simulation to analyze binding in protease active site; no biophysical or genetic validation to confirm specificity.	Lin et al., 2017, 2016
Peptide inhibitors with CONH2 and boronic acid warheads	8 each	fluorescence resonance energy transfer (FRET)-based NS2B/3 protease assay	Best compound, **7** (Bz-(4-guanidino)Phe-Arg-B(OH)2; DENV2 K_i = 27 nM; IC_{50} = 36 nM; EC_{50}/CC_{50} = 18/>100 μM	DENV and WNV NS2B/3 protease; confirmed by X-ray crystallography; no genetic validation.	Nitsche et al., 2017
high throughout synthesized cyclic octapeptides	33	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Boc–Gly–Arg–Arg–MCA	Best peptide, **22** has IC_{50}= 0.95 μM; most cellular active peptide, **33,** has IC_{50}= 2.1 μM and EC_{50}/CC_{50} = 11.4/129 μM.	DENV NS2B/3 protease; binding in active site analyzed by in silico docking; no biophysical or genetic validation.	Takagi et al., 2017
fused bicyclic compounds of pyrrolidino and imidazolidinone derivatives	not stated	in vitro DENV2 NS2B/3 protease assay; fluorescent peptide substrate, Bz-Nle-Lys–Arg–Arg–MCA	Fused pyrrolidino [1,2-c]imidazolidinone compound, **2** has IC_{50}= 1.2 μM (competitive to nucleotide incorporation) and DENV2 EC_{50} = 39 μM.	DENV NS2B/3 protease; binding site in active analyzed by in silico docking; no biophysical or genetic validation.	Weng et al., 2017; Zhou et al., 2013
Library of active-site metal ion chelator	n.a	In vitro filter-binding DENV RdRp assay	DMB220 (pyridoxine-derivative); DENV1-4 RdRp IC_{50} and EC_{50}/CC_{50} = 5-6.7 μM and 2.2-2.8/>50 μM; inactive against HIV RT and weakly active against HIV integrase.	DENV RdRp; S600T mutation in RdRp conferred 3-fold increase in IC_{50}. In silico docking of compound in RdRp; no biophysical or genetic validation.	Xu et al., 2016; Stranix et al., 2009.
Peptidomimetics (N-capped-Capped (Bz-Arg-Lys- 4-hydroxyphenylglycine-NH_2	< 100*	fluorescence resonance energy transfer (FRET) with substrate Abz-Nle-Lys-Arg-	**104**, DENV2 K_i = 18 nM; EC_{50}/CC_{50} = 3.4/>100 μM. Inactive against thrombin and	DENV NS2B/3 protease; binding in active site analyzed by in silico	Behnam et al., 2015*, 2014; Nitsche et al., 2013, 2012

tripeptides)		Arg-Ser-3-(NO_2)Tyr and HPLC-based NS2B/3 protease assays	trypsin.	docking; competitive fluorescence quench assay with aprotinin confirmed binding to protease active site; no genetic validation.	
Peptide inhibitors with phenylalanine and phenylglycine analogues as arginine mimetics for S2 pocket.	24	fluorescence resonance energy transfer (FRET) assay with substrate Abz-Nle-Lys-Arg-Arg-Ser-3-(NO_2)Tyr	Most potent compound, **42a**, DENV IC_{50} = 210 nM, K_i = 139 nM; not active against WNV protease, trypsin.	DENV NS2B/3 protease; binding in active site analyzed by in silico docking; competitive fluorescence quench assay with aprotinin confirmed binding to protease active site; no genetic validation.	Weigel et al., 2015
Capsid peptides	2	Atomic force microscopy-based force spectroscopy, dynamic light scattering, NMR and computational analysis	Peptide comprising aa14-23 of DENV Capsid protein, IC_{50} and EC_{50} not determined	Inhibits capsid binding to perilipin 3 in lipid droplets (LD), ApoE in very low-density lipoproteins (VLDLs). No genetic validation.	Faustino et al., 2015a, b, 2014; Martins et al., 2012
S-adenosyl-homocysteine analogues	12	in vitro DENV3 MTase N7 and 2'-*O* MTase assay	Compound 10, N7 and 2'-*O* IC_{50} = 0.82 and 0.17 µM, respectively.	DENV MTase; compound binding confirmed by X-ray crystallography, No genetic validation.	Lim et al., 2011

Table 4. Compound screening with in silico docking and modeling in X-ray structures of DENV proteins.

Inhibitors Type/Source	Library size	Screening Assay/Method	Inhibitor	DENV/Host Target	Reference
NCI diversity set II library	24,428	In silico docking of apo-DENV NS2B/3 protease X-ray crystal structure (2FOM) using AutoDock Vina program; fluorescence-quench NS2B/3 protease assay with heptapeptide; split luciferase complementation (SLC)-based conformational switch assay to monitor NS2B conformational changes upon binding to NS3 protease	Tested top 29 hits; NSC135618, DENV2 IC_{50} = 1.8 μM (hill coefficient = 0.7; non-competitive mode of inhibition); EC_{50} = 0.81 μM; A549 CC_{50} = 48.8 μM; inhibits ZIKV, YFV and WNV cell-based assays at low micromolar activities.	Likely NS2B/3 protease; binding confirmed with biophysical (thermal shift; Tm increased by 2.6-4.8 ^{o}C) using WT and mutant proteins and biochemical ZIKV protease cleavage assay. No genetic validation to confirm specificity.	Brecher et al., 2017
Maybridge database (using ICM software)	110,000	In silico docking of DENV Env β-OG binding site; DENV firefly luciferase reporter infectious virus assay	23 hits; compounds **2** and **5** with DENV2 EC_{50} = 3.1 and 5 μM, respectively; BVDV EC_{50} >50 μM; CC_{50} >100 μM; compound **2** docked into DENV Env β-OG binding site.	Maybe DENV Envelope. No biophysical or genetic validation to confirm specificity.	Leal et al., 2017
Pyrazole analogs	Not stated	In silico docking of allosteric pocket of apo-DENV NS2B/3 protease X-ray crystal structure (2FOM) using PLANTS; DENV NS2B/3 protease assay with Boc-Gly-Arg-Arg-AMC	Compounds **4**, **5**: NS2B/3 protease IC_{50} = 5-7 μM; DENV2 cell-based protease and infection assays, EC_{50}= 5-8 μM; compound **4** (1 mg/kg) protected mice from lethal dose of intracerebrally injected DENV.	Maybe DENV NS2B/3 protease; no biophysical or genetic validation to confirm specificity.	Pelliccia et al., 2017
PubChem	210,903	In silico docking of apo-DENV NS2B/3 protease X-ray crystal structure (2FOM) using AutoDock Vina program; DENV NS2B/3 protease assay with Boc-Gly-Arg-Arg-AMC.	5 hits tested; CID54681617, CID54692801 and CID54715399; DENV2 IC_{50} values (μM) and viral titer reduction assay = 19.9 & 79.9%; 17.5 & 69.8% and 9.1 & 73.9%, respectively.	Maybe DENV NS2B/3 protease; no biophysical or genetic validation to confirm specificity.	Cabaracas-Montalvo et al., 2016

PubChem[a] and SuperNatural II database[b]	372792 (47,473 small molecules and 325,319 natural products)	Homology models of DENV1-4 RdRp; in silico docking into RdRp RNA tunnel using AutoDock/Vina programs	39 compounds predicted to bind; IC_{50} not reported.	Maybe DENV3 RdRp; no biochemical, biophysical or genetic validation to confirm specificity.	Galiano et al., 2016
plant-derived secondary metabolites	2,194	In silico docking of DENV envelope, helicase, protease, MTase and RdRp X-ray crystal structures and NMR structures using Molegro Virtual Docker (version 6.0, Molegro ApS, Aarhus, Denmark)	25 hits for NS2B/3 protease; 21 hits for NS3 helicase; 15 hits for MTase; 1 hit for RdRp; 31 hits for Envelope. Most frequent binders: Polyphenolic compounds, flavonoids, chalcones, and other phenolics; IC_{50} not reported	DENV envelope, helicase, protease, MTase and RdRp; no biochemical, biophysical or genetic validation to confirm specificity.	Powers and Setzer 2016
In-house library of HCV NS5B inhibitors	203	In silico docking into DENV3 RdRp X-ray crystal structure (2J7U) using AutoDock 4.2 software package	HeE1-2Tyr (pyridobenzothiazole derivative; non-competitive mode of inhibition), DENV3 IC_{50} =1.5 μM; DENV1-4 EC_{50}= 6.8-15 μM.	DENV3 NS5 RdRp (binding site determined by X-ray crystallography is in Site 1 between fingers domain and the priming loop); binds in the same region as NITD-107.	Tarantino et al., 2016
ChemBridge Corporation (San Diego, CA), Enamine (Kyiv, Ukraine), Life Chemicals (Niagara□ on□the□Lake, ON), Maybridge Chemicals, Thermo Fisher Scientific Inc., Janssen Pharmaceutical (Belgium).	5 million	In silico docking of DENV NS2B/3 protease X-ray crystal structure with nKRR-H inhibitor (3U1I) using Molecular Operating Environment Molecular Operating Environment (MOE) software, Chemical Computing Group Inc.) and AutoDock (The Scripps Research Institute); DENV NS2B/3 protease assay with Bz-nKRR-AMC.	14 hits; compound **14** shows 85.3% at 300 μM inhibition in NS2B/3 protease assay; EC_{50} = 5 μM	Maybe DENV NS2B/3 protease; no biophysical or genetic validation to confirm specificity.	Li et al., 2015
Src tyrosine protein kinase active sca□olds (databases of bioactive molecules from ChEMBL, BindingDB) and internal collection of kinase inhibitors	≤ 3000 Src inhibitors and ≤10000 virtual analogs	In silico docking of DENV3 NS5 RdRp allosteric site (cavity B) using Glide Standard Precision docking protocol and Autodock Vina; NS3−NS5 AlphaScreen assay	22 compound tested; compound **16i** (purine derivative) with DENV EC_{50} = 5.3 μM; CC_{50} = 168 μM	May inhibit DENV NS3−NS5 interaction; no biophysical or genetic validation to confirm specificity.	Vincetti et al., 2015

(A) Subset of the ZINC database with "drug-like" properties (selected from ChemBridge Corporation , ChemDiv Inc. (San Diego, CA), Ryan Scientific Inc. (Mount Pleasant, SC), Maybridge Chemical Company, Sigma-Aldrich); (B) Focused library from ChemBridge and Maybridge Chemical with clogP filters.	(A) 642,769 (B) 45 458	DrugDiscovery@TACC portal; in silico docking of DENV NS2B/3 protease X-ray crystal structures with (3U1I and 3U1J) and without (2FOM) bound inhibitors using autodock Vina program on supercomputer resources at the Texas Advanced Computing Center; DENV NS2B/3 protease assay with BocGRR-AMC.	ZINC04321905; DENV NS2B/3 protease K_i = 7 μM with mixed noncompetitive inhibition.	Maybe DENV NS2B/3 protease; no biophysical or genetic validation to confirm specificity.	Viswanathan et al., 2014
MOE lead-like database	661,417	In silico docking of DENV NS2B/3 protease X-ray crystal structure (2FOM) at the NS3-NS2B interaction region using MOE software	39 hits tested; SK-12 (noncompetitive inhibitor); DENV1-4 EC_{50} = 0.7-2.4 μM; JEV EC_{50} = 29.8 μM; in silico modeling in NS2B binding site of NS3 protease.	Maybe DENV NS2B/3 protease; no biophysical or genetic validation to confirm specificity.	Pambudi et al., 2013
Library of Pharmacologically Active Compounds (LOPAC), Sigma-Aldrich	1280	In silico docking (AutoDock4 software package) of a model of WNV NS3 helicase X-ray crystal structure (2QEQ) with ssRNA.	3 hits tested; Ivermectin (DENV IC_{50} = 500±70 nM; EC_{50} = 700 nM (virus reduction assay) and <1 μM (CPE assay); K_i = 354 nM; uncompetitive inhibition. Mutations T408A and D409A in helicase protein abolish inhibitory activity. Also inhibits WNV, YFV, TBEV, JEV but not BVDV nor HCV.	Maybe DENV helicase; no biophysical or genetic validation to confirm specificity.	Mastrangelo et al., 2012

Table 5. Compound Screening with DENV cell-based assays

Inhibitors Type/Source	Library size	Screening Assay/Method	Inhibitor	DENV/Host Target	Reference
Mammalian Ser/Thr, Tyr and lipid kinase inhibitors from Calbiochem (San Diego, CA), Sigma-Aldrich (St. Louis, MO), Pierce (Rockford, IL), re-synthesized clinical-stage inhibitors)	>120	DENV infection of Vero cells (IFA, fluorescence detection); 384 well format	Imatinib, dasatinib, GNF-2 (4,6 disubstituted pyrimidine), AZD0530, 2,4-diamino pyrimidines, DENV2 EC_{50} from 5-20 μM	c-Src, Abl and Fyn kinases and block DENV particle formation by binding to DENV Envelope in ER; validated by siRNA knockdown	de Wispelaere et al., 2018, 2013; Clark et al., 2016; Chu and Yang, 2007
in-house library	not stated	In vitro screen with DENV-2 luciferase reporter replicon assay; inhibitions tested with DENV2 whole virus infection assay	SAR exploration from hit compound, 10e; compound **14l** (phthalazinone derivative); DENV2 EC_{50} value of 0.13 μM	under investigation (proposed as NS2B/3 protease based on docking studies); no biochemical, biophysical or genetic validation to confirm specificity.	Lu et al., 2018
Shionogi antiviral compounds library	7000	DENV-induced cytopathic (CPE) assay	compound-B (benzimidazole derivative); DENV1-4 EC_{50}s = 1.32-4.12 μM	NS4A; compound resistant virus, has C87S mutation in NS4A.	Nobori et al., 2018
chemically diverse compounds National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (Harvard Medical School, Boston, MA)	51,000	Human foreskin fibroblasts, stably expressing human telomerase reverse transcriptase and IRF3/IFN-responsive pGreenFire-ISRE lentivector.	AV-C ((2-fluorophenyl)-2-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1,2-dihydrochromeno[2,3-c]pyrrole-3,9-dione); DENV2 EC_{50} from 9.9 μM	agonist of TRIF signaling pathway, induces IRF3 expression and type I interferon secretion; IPS-1/MAVS involved in Flavivirus replication. Validated with CRISPR/Cas9-mediated genome editing in cells.	Pryke et al., 2017
MicroSource (2,000 known drugs, experimental bioactives, and pure natural products), Prestwick Chemical Library (1,119 off- patent drugs), Tocris, CRL, BioFocus, SPECS	5632	DENV2 infection of HEK293 cells (high content imaging, fluorescence detection); 384 well format	SAR exploration of 39 analogs; VGTI-A3, VGTI-A3-03 (DENV2 IC_{90} = 112 and 40 nM, respectively)	Binds to DENV capsid pocket involved in dimerization and associates with secreted virus particles; compound resistant	Smith et al., 2018, Shum et al., 2010

				virus, has T25L, L35P, L38M mutations in capsid.	
			SKI-417616 (dihydrodibenzothiepines derivatives); DENV2 EC_{50} = 1.2 μM; CC_{50} = 43.2 μM; also inhibits DENV-1, -3, -4, WNV, SINV at similar potency.	Inhibits Dopamine Receptor D4 and Downstream Mitogen-Activated Protein Kinase Signaling (through blocking ERK phosphorylation); chemical validation with known inhibitors.	Smith et al., 2014a.
			methotrexate (MTX) and floxuridine (DENV2 IC_{50} = 90 and 60 nM, respectively); also inhibits DENV-1, -3, -4, WNV at similar potency. No efficacy in lethal DENV mouse model.	MTX= dihydrofolate reductase; floxuridine = uracil analog, inhibits thymidylate synthase; chemical validation with thymidine precursor.	Fischer et al., 2013
Chemical Diversity Lab (San Diego, CA)	60,000	DENV-2 luciferase reporter replicon in BHK21 cells	BP13944, DENV2 EC_{50} = 1.03 ± 0.09 μM; active on DENV-1, -3 and -4.	DENV NS2B/3 protease; compound resistant DENV2 replicon has E66G mutation in NS3 protease.	Yang et al., 2014
Janssen Pharmaceutical in-house library	not stated	DENV-2 luciferase reporter replicon	JNJ-1A, DENV1-4 EC50 = 0.7 μM; equally potent on DENV-1, -3, -4.	DENV NS4B; compound resistant DENV2 replicon has T108I mutation in NS4B; P104L/A119T mutation in NS4B also abolished inhibition; same as NITD-618.	Hernandez-Morales et al., 2017
			SDM25N	γ opioid receptor antagonist, DENV EC_{50} = 1.9 μM; compound resistant DENV2 replicon has F164L mutation in NS4B; P104L mutation in	van Cleef et al., 2013

				NS4B also abolished inhibition; same as NITD-618 and JNJ-1A.	
Chemical library from the Centre for Drug Design and Discovery (CD3); KU Leuven	not stated	DENV2-induced CPE in Vero-B cells (7 day assay)	compound **1** (acyl-indole derivative), DENV2 EC_{50}/CC_{50} = 0.078/29 µM; extensive SAR exploration resulted in compound **12a** (dimethoxyaniline analogue, (+)-enantiomer) DENV2 EC_{50}/CC_{50} = 0.007/16 µM	NS4B; compound resistant DENV2 has mutation in NS4B (amino acid not stated).	Bardiot et al., 2018
			compound **14** (purine pyrazolyl derivative) ; DENV2 EC50/CC50 = 1.9/>109 µM	Proposed NS5 RdRp; in silico docking in cavity B; no biophysical or genetic validation to confirm specificity.	Venkatesham et al., 2017
			compounds **6b**, **6d** and **7a** (pyrazine dicarboxamide derivatives), DENV2 EC50/CC50 = 0.5/>116 µM	Not determined	Saudi et al., 2016
			compounds **15b** (imidazole dicarboxamide derivative), DENV2 EC_{50}/CC_{50} = 2.5/>120 µM; compounds **20a** and **20b** (pyrazine dicarboxamide derivatives), DENV2 EC_{50}/CC_{50} = 0.94/>117.5 µM.	Not determined	Saudi et al., 2014a
Selleckchem bioactive compound library (FDA-approved drugs and known bioactives)	≤ 2,000	ZIKV infection of U2OS cells (high content imaging, fluorescence detection); 384 well format	nanchangmycin (IC_{50} not determined); active against ZIKV, WNV, CHIKV.	Receptor Tyrosine Kinase, AXL; proposed as attachment receptor for Flaviviruses; no chemical or genetic validation to confirm specificity.	Rausch et al., 2017

Novartis in-house library	1.8 million	DENV-2 luciferase reporter replicon; counter-screen with HCV replicon	Hit, compound **1** (spiropyrazolopyridon derivative), DENV2 EC_{50} =14 nM (HCV replicon EC_{50} > 5 μM); extensive SAR exploration; compounds **14a**; DENV-2 and -3 EC_{50} = 42/76 nM; DENV-1 and -4 EC_{50} > 1 μM; treatment with 5, 25, and 50 mg/kg of compound14a (BID) reduced mouse viremia by 1.7-, 10-, and 39-folds.	DENV NS4B; compound resistant DENV2 has V63A/L/M/S/T mutations in NS4B.	Wang et al., 2015; Zou et al., 2015
			NITD-618 (aminothiazole derivative); DENV1-4 EC_{50}/CC_{50} = 1.0-4.1 μM/>40 μM	DENV NS4B; compound resistant DENV2 replicon has P104L and A119T mutation in NS4B.	Xie et al., 2011
		DENV-induced cytopathic (CPE) assay	NITD-982 (isoxazole-pyrazole derivative); DENV2 EC_{50}/CC_{50} = 2.4 nM/>5 μM	inhibits host dihydroorotate dehydrogenase involved in de novo pyrimidine biosynthesis; validated by binding assay, brequinar and uridine addition in DENV cell-based assay	Wang et al., 2011a
			Hit, NITD2636 has DENV-2 EC_{50} =0.55 μM; extensive SAR exploration; NITD-451 (benzomorphan derivative); DENV2 EC_{50}/CC_{50} = 160 nM/>50 μM; treatment with 25 mg/kg of compound14a (QD) reduced mouse viremia by about 40-folds.	viral RNA translation; validated with biochemical and cell-based assays.	Wang et al., 2011b
Not stated	≤ 200,000	DENV2 infection of Vero cells (CPE measurement); 96 well format	ST-148 (Maybridge); DENV1-4 EC_{50}/CC_{50} = 16-2800 nM/>100 μM; treatment with 50 mg/kg of compound (QD)	DENV capsid, ST-148 enhanced capsid protein self-interaction; compound resistant	Byrd et al., 2013a; Scaturro et al., 2014

			reduced mouse viremia by about 52-folds.	DENV2 has S34L mutation in capsid; validated by intracellular BRET assay.	
			ST-610 (benzoxazole derivative; ChemBridge); DENV1-4 EC_{50} = 45-377 nM; treatment with 100 mg/kg of compound (QD or BID) reduced mouse viremia by about 5-folds.	Inhibits DENV helicase unwinding activity but not ATPase activity; compound resistant DENV2 has A263T mutation in helicase.	Byrd et al., 2013b
bioactive lipid library Biomol (Enzo) supplemented with additional commercial compounds.	212	DENV infection of Vero cells (IFA, fluorescence detection); 384 well format	4-hydroxyphenyl retinamide (4-HPR); DENV2 EC_{90}= 2 μM; U18666A; also active on WNV, HCV, Modoc virus; treatment with 180 mg/kg of compound (QD) reduced mouse viremia by about 1.7-folds.	Inhibit DENV RNA synthesis likely via host pathway; mechanism of action not determined.	Carocci et al., 2015; Chu and Yang, 2007

Table 6. DENV NIs.

Base	Modification (Name)	Assays	anti-DENV activity: EC_{50}/CC_{50} [IC50] μM	POLRMT SNIR[#] IC_{50} μM [% inhibition]	Reference
Adenosine (A)	2'-C-methyl-A	DENV2 infection in Vero cells [DENV2 in A549 cells]	4/18 [1.1/>50]*	62[a]; [>30[b]]	Migliaccio et al., 2003; Chen et al., 2010a*
	7-deaza-2'-C-methyl-A (7DMA, MK-0608)	DENV2 infection in Vero cells	15/>320	n.d.	Schul et al., 2007; Olsen et al., 2004
	2'-C-acetylene-A	DENV2 infection in A549 cells	1.4/>50	n.d.	Chen et al., 2010a
	7-deaza-2'-ethynyl-A (NITD008)	DENV2 infection in A549 cells & human PBMCs*	0.7/>100; 0.18-28/>25*	91[a]	Yin et al., 2009; Chen et al., 2010b*
	7-deaza-7-F-2'-acetylene-A	DENV2 infection in A549 cells	0.42/44	n.d.	Chen et al., 2010a
	7-deaza-7-cyano-2'-acetylene-A	DENV2 infection in A549 cells	3.1/>100	n.d.	
	7-deaza-7-ethanamide-2'-acetylene-A	DENV2 infection in A549 cells	2/62	n.d.	
	2′-C-acetylene-7-deaza-7-carbamoyl-A (NITD449)	DENV1-4 infection in Vero and A549 cells and human PBMCs	1.62–6.99/>50	n.d.	Chen et al., 2010b
	3′,5′-O-diisobutyryl-prodrug of NITD449 (NITD203)	DENV1-4 infection in Vero and A549 cells and human PBMCs	0.1–0.71/>50	n.d.	
Guanosine (G)	2'-C-Methyl-G	DENV2 infection in Vero cells	13.6/>60	[□70[b]]	Migliaccio et al., 2003
	aryl-phosphoramidate prodrug of 6-O-methyl-2′-C-methyl-G (INX-08189)	DENV2 replicon in Huh7 cells	0.014/>1	32[a]	Yeo et al., 2015
Cytosine (C)	2'-C-methyl-C	DENV2 subgenomic replicon I & whole virus infection in Huh7 cells	11.2 [19.5]	129[a]; [>60[b]]	Lee et al., 2015

	2'-deoxy-2'-F-2'-C-methyl-C (PSI-6130)	DENV2 subgenomic replicon & whole virus infection in Huh7 cells	>50	n.d.	
	4'-azido-C (R1479)	DENV2 infection in human PBMCs	0.1-0.25/>25;	2.6[a]; [100[b]]	Chen et al., 2014
	tri-isobutyl ester prodrug of R1479 (Balapiravir, R1626)	DENV2 infection in Huh7 cells, human primary macrophages and dendritic cells	1.9–11/>2000	n.d.	Nguyen et al., 2013
Uridine (U)	phosphoramidate prodrug of 2′-C-methyl-U (24)	DENV2 infection in human PBMCs	0.19 />50 [5]	>300[a] [29.4]	Wang et al., 2018
	phosphoramidate prodrug of 2′-C-ethynyl-U (27)	DENV2 infection in human PBMCs	0.45 />50 [1.6]	[16.8]	
	phosphoramidate prodrug of 2′-C-propynyl-U (29)	DENV2 infection in human PBMCs	1.9 />50 [2]	[6.7]	
	phosphoramidate prodrug of 2′-C-methyl-4'F-U (35)	DENV2 infection in human PBMCs	1.1 />50 [6.6]	[5.7]	
	phosphoramidate prodrug of 2'-C-ethynyl-4'-F-U (37)	DENV2 infection in human PBMCs	0.19 />50 [0.65]	[3]	
	phosphoramidate prodrug of 2′-deoxy-2′-F-2′-C-methyl-U (Sofosbuvir; PSI-7977)	DENV2 infection in human PBMCs	1.2/>20 [18]	[1.8; <3[b]]	
		DENV2 CPE and PRNT* assays in Huh7 cells	4.9 µM/>100 and 1.4* [14.7]	n.d.	Xu et al., 2015
		DENV2 subgenomic replicon & whole virus infection in Huh7 cells	>50	n.d.	Lee et al., 2015
	3', 5' -di-*O*-trityl-5-fluoro-2' -dU	DENV2-induced CPE in Vero-B cells (7 day assay)	1.2/>50	n.d.	Saudi et al., 2014b
	3', 5' -di-*O*-trityl-2'-dU (Compound 2a)	DENV2-induced CPE in Vero-B cells (7 day assay)	2.7/>65	n.d.	Chatelain et al., 2013
	3' ,5'-di-*O*-trityl-U	DENV2-induced CPE in Vero-B cells (7 day assay)	2/>100	n.d.	De Burghgraeve et al., 2013
	2' ,5' di-*O*-trityl-U	DENV2-induced CPE in Vero-B cells (7 day assay)	30/>100	n.d.	

Modified nucleobase and nucleoside	ribavirin nucleobase	DENV2 replicon in Huh7 cells	4.9/>1000	n.d.	Lin et al., 2018
	ribavirin	DENV2 replicon in Huh7 cells	1.3/20	[<10[b]]	
	mizoribine nucleobase	DENV2 replicon in Huh7 cells	2.4/23	n.d.	
	mizoribine	DENV2 replicon in Huh7 cells	15/33	n.d.	
	T-1105	DENV2 replicon in Huh7 cells	21/>665	n.d.	
	T-1105 riboside (T-1106)	DENV2 replicon in Huh7 cells	113/>1000	n.d.	
	diamino-purine	DENV2 replicon in Huh7 cells	3.6/13	n.d.	
	diamino-purine riboside	DENV2 replicon in Huh7 cells	27/31	n.d.	
	T-705 (favipiravir)	DENV2 replicon in Huh7 cells	110/>1000	221[a]; [>90[b]]	

[#] mitochondria RNA Polymerase single nucleotide incorporation assay

[a] Jin, Z., Kinkade, A., Behera, I., Chaudhuri, S., Tucker, K., Dyatkina, N., Rajwanshi, V.K., Wang, G., Jekle, A,, Smith, D.B., Beigelman, L., Symons, J.A., Deval, J. 2017. Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Res. 143, 1–43.

[b] Arnold, J.J., Sharma, S.D., Feng, J.Y., Ray, A.S., Smidansky, E.D., Kireeva, M.L., Cho, A., Perry, J., Vela, J.E., Park, Y., Xu, Y., Tian, Y., Babusis, D., Barauskus, O., Peterson, B.R., Gnatt, A., Kashlev, M., Zhong, W., Cameron, C.E., 2012a. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog. 8, e1003030.



Nature Reviews | Microbiology

Highlights

1. Review the strategies for dengue drug discovery

2. Review the major breakthroughs in dengue drug discovery

3. Provide prospective for future dengue drug discovery